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Summary
The absorbed dose assessment in the presence of tissue heterogeneities in external ra-
diotherapy is an issue that has concerned the medical physics community for almost
three decades and it is still a matter of concern. Aiming to obtain dose distributions
in clinically-acceptable computation times, analytical dose calculation algorithms in-
tegrated in treatment planning systems based their calculations on water-equivalent
properties and elemental compositions of each material are disregarded despite the fact
that radiation interaction processes strongly depend on them. This approximation
provides reasonable accuracy in water-like tissues but the reliability of predicted dose
distributions in the patient might be questioned when the radiation beam is traversing
complex density heterogeneities, such as air, lung or bone. Experimental verification
of dose calculation algorithms is essential and ionization chambers (IC) are the refer-
ence detectors for this purpose. However, correction factors to determine the absorbed
dose in materials other than water are unknown for most IC types and therefore, they
cannot procure reliable measurements in heterogeneous media. Monte Carlo (MC) sim-
ulations offer a high precision in dose calculation by tracking all particles individually
taking into account the specific properties of each material. Unfortunately, accuracy
and computation speed are inversely proportional and MC-based approaches generally
entail long calculation times, unaffordable in the clinical routine. Nevertheless, for the
cases where the expected errors in the predicted dose distributions during treatment
planning are significant, i.e. when the radiation beam path is highly inhomogeneous,
the benefit of resorting to MC dose calculations to achieve higher accuracy would be
undoubtedly worth a presumably long computation time.
In this thesis the suitability of several detectors to accurately determine the ab-
sorbed dose in the presence of high-density heterogeneities was evaluated. Ultra-thin
thermoluminescent detectors (TLDs) and radiochromic films were considered as poten-
tial candidates for entailing low perturbation effects. MC dose calculations enabled to
validate and understand the experimental results. Further, both dosimetric techniques
were employed to thoroughly examine the behavior of a recently-released non-analytical
dose calculation algorithm (AXB)—which copes with the elemental composition of ma-
terials and thus, is claimed to yield promising results—in heterogeneous phantoms. Fi-
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nally, a fast algorithm named the heterogeneity index (HI) was developed to quantify
the level of patient tissue heterogeneities traversed by the radiotherapy beam. The va-
lidity of this HI to easily predict the accuracy of dose distributions based on analytical
dose calculations was analyzed by evaluating the correlation between the HI and the
dose uncertainties estimated by using MC as the reference.
The results show that a detector of 50µm thickness can provide reliable absorbed
dose measurements in high-density heterogeneities since perturbation correction factors
are unneeded. AXB was found to provide comparable accuracy to MC dose calculations
in the presence of heterogeneities but uncertainties in the material assignment procedure
might lead to significant changes in the dose distributions, which deserves a word of
caution when carrying out experimental verifications. Finally, HI was found to be
a fast and good indicator for the accuracy of dose delivery in terms of tumor dose
coverage. Accordingly, HI can be implemented in the clinical routine to decide whether
or not a MC dose recalculation of the plan should be considered to ensure that dose
uncertainties are kept within tolerance levels. In conclusion, this thesis work tackled
the main concerns on the absorbed dose calculation and measurement in the presence
of tissue heterogeneities.
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Chapter 1
Introduction
1.1 Cancer incidence
Cancer is a group of diseases characterized by uncontrolled growth and spread of ab-
normal cells that may end up forming malignant tumors. Cancer is a leading cause
of death worldwide, accounting for 7.6 million deaths (around 13% of all deaths) in
20081. Figure 1.1 shows the cancer incidence worldwide grouped by tumor type. The
5-year relative survival rate for all cancers diagnosed between 2002 and 2008 is 68%,
up from 49% in 1975-1977, which reflects both progress in diagnosing certain cancers
at an earlier stage and improvements in treatment2.
Cancer treatment requires a careful selection of one or more intervention, such
as surgery, radiotherapy, and chemotherapy—based on the tumor type, location and
stage. At present, radiation therapy contributes to the cure of approximately 70% of
all cancer patients, when used alone or in combination with surgery or chemotherapy-
immunotherapy. This proportion illustrates the important role of radiation therapy in
cancer management3.
In radiotherapy (RT) treatments ionizing radiation is used to damage the tumor
Figure 1.1: Worldwide cancer incidence. From the World Health Organization (WHO)1, 2013.
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Figure 1.2: Percent depth-dose deposition curves for electron, photon, proton and carbon ion beams.
From Cern Courier, International Journal of High-Energy Physics, December 6, 2006.
cells either by direct break-up of DNA structure or by indirect interactions of free
radicals generated from the ionization of water followed by DNA oxidation. RT has
two main modalities: external beam RT and brachytherapy4. In external beam RT,
the radiation source is external to the patient whereas in brachytherapy radioactive
seeds are placed inside the patient in direct contact with the tumor. This thesis will be
focused on external beam RT treatments to which we will refer as RT for abbreviation.
1.2 RT basis
Different types of particle RT co-exist nowadays and the appropriate choice among them
depends on many factors such as the type of tumor, its size and location, the patient age
and the availability of the technique. Tumors can be treated with electrons, photons,
protons or heavier ions beams. Characteristic dose distributions in water are depicted
in figure 1.2 for all particles.
1.2.1 Megavoltage (MV) electron and photon beams
Two of the oldest and most popular modalities are MV electrons and photon beams.
Both electron and photon RT beams are commonly generated by modern linear accel-
erators (linacs). Electrons are accelerated to kinetic energies ranging from 6 to 25 MeV
using microwave radiofrequency fields. Electrons impinge on a scattering foil in order
to obtain a wider beam to cover the tumor area and then a set of collimators shape
the beam according to the tumor contour. The characteristic fall-off in depth of MV
electron beams makes them suitable for the treatment of superficial tumors—such as
skin tumors.
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Figure 1.3: Linac accelerator head for electron and photon radiotherapy. From Varian Medical
Systems web.
Figure 1.4: Schematic representation of the basic components of the head of a linac for photon (A)
and electron (B) radiotherapy. From Khan 4 .
MV photon beams are produced by the rapid deceleration of electrons in a high-
density target (bremsstrahlung photons). The dose distribution in depth of MV photon
beams is characterized by a steep dose gradient within the first millimeters of tissue
which is known as the build-up region. This kind of therapy can be useful in a wide
range of cases. Usually, a treatment involves several fields entering the patient from
different angles, in such a way that they all aim at the tumor. A scheme of a typical
accelerator gantry is shown in figure 1.3.
The main components of a linac in electron and photon mode are shown in figure
1.4. Further information about electron and photon therapy can be found elsewhere5.
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1.2.2 Proton and heavier ion beams
It was not until the beginning of the 1990’s that radiation oncologists started to recog-
nize proton therapy as a therapeutic method. By 1993 about 10,000 patients worldwide
had been treated with protons. In 2010, there were 28 centers for proton therapy around
the world; by the end of 2006 this has reached 50,000. Last year, the Particle Ther-
apy Co-Operative Group (PTCOG) registered a total of 73,804 patients treated with
protons since the first facility—Loma Linda (California, USA)—was built. Today five
companies supply turnkey proton-therapy facilities.
The depth-dose distribution which characterizes proton’s interaction with matter is
known as the Bragg-peak curve, and it is very sharp for a given beam energy (see figure
1.2). Protons deposit the vast majority of their energy at the end of their trajectory—
where the tumor should be located. The sharp fall-off1 of the proton dose deposition
after the Bragg-peak leads to a significant reduction in the dose deposited beyond
the tumor site (see figure 1.2). All in all, the characteristic depth-dose distributions
of proton beams result in a significantly reduced integral dose compared to photon
treatments6.
Two main beam delivery methods co-exist nowadays: the passive-scattering tech-
nique and the active scanning technique. In passive spreading techniques, the proton
beam is spread by placing scattering material into the path of the protons. A single
scatterer broadens the beam sufficiently for treatments requiring small fields. For larger
fields, a second scatterer is needed to ensure a uniform dose profile. A combination
of custom-made—patient-specific—collimators (commonly named apertures) and com-
pensators conform the dose to the target volume laterally and distally, respectively
(see figure 1.5). The spread out Bragg peak (SOBP), shown in shown in figure 1.6, is
obtained via a set of range modulator wheels or ridge filters inside the nozzle of the
delivery system.
In scanning-beam techniques, magnets deflect and steer the proton beam. Under
computer control, a narrow mono-energetic beam paints the treatment volume, voxel-
by-voxel, in successive layers. The depth of penetration of the Bragg peak is adjusted
by varying the energy of the beam before it enters the nozzle. The delivery is done
either in a step-and-shoot mode or continuously. The two techniques are described
schematically in figure 1.7.
In 1975 a heavy ion therapy program began at the Lawrence Berkeley National
Laboratory where, until 1992, 2054 patients were treated with helium ions and 433
with heavier ions (Ne, N, O, C, Si and Ar). Currently, heavy ion therapy is performed
at three centers—two in Japan and one in Germany—using carbon ions and around
3500 patients have been treated.
Ion beams have two important features arising both from the physical aspects of
1The fall-off is usually considered to be the distal region of the Bragg peak where the dose decreases
from 80% to 20%.
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Figure 1.5: Patient-specific devices for dose conformation to the tumor in passively-scattered proton
therapy fields.
Figure 1.6: Generation of an SOBP for passively-scattered proton beams. From McGowan, Burnet,
and Lomax 7 .
Figure 1.7: Generation of an SOBP for passively-scattered proton beams. Extracted from Hall 8 .
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their dose distribution in the patient and from potentially advantageous biological phe-
nomena resulting from their high rate of energy deposition (high linear energy transfer
(LET)) over a portion of the particle track which can often be located in the tumor
volume. Probably the most important of these biological phenomena is a markedly
increased efficiency of cell killing, i.e. the relative biological effectiveness (RBE2) of
heavy ions is higher than that of protons. Thus, a lower dose is needed with heavy
ion beams to produce the same cell damage. On the other hand, the main drawback
of this kind of therapy is that the nuclear fragmentation of the heavy ions produces
secondary charged fragments. These are responsible for the extra dose tail beyond the
Bragg peak as it can be appreciated in figure 1.2. This tail might damage the healthy
tissue behind the tumor during treatment.
Further information about the history and future developments of heavy ion therapy
can be found elsewhere10.
This thesis work will be focused on photon and proton RT.
1.3 Uncertainties in RT
Radiotherapy, as well as the rest of disciplines that aim to overcome cancer, undergoes
continuous development in all steps involved in the treatment procedure. Techno-
logical advances in imaging and patient positioning, development of dose calculation
algorithms integrated in treatment planning systems (TPS), progress in gated treat-
ments to account for inter-fractional geometry changes in the patient and advances in
delivery techniques—such as intensity-modulated radiation therapy (IMRT)—, lead to
better accomplish the main goal of radiotherapy: to ensure maximum tumor coverage
while sparing surrounding healthy tissues which will lead to mitigate the severity of
side effects and lower the risk of secondary malignances11.
The aforementioned areas of advance in radiotherapy are, at the same time, sources
of uncertainty in the assessment of the delivered dose to the patient12–17, i.e. the
precision and quality of a treatment are limited by the daily reproducibility of patient
positioning in the radiation field, the ability to locate and delineate the tumor volume
on a planning image and the accuracy in the predicted dose distributions. A difference
in absorbed dose of about 10% is detectable in tumor control, and a difference of about
7% in absorbed dose can be observed for a number of normal tissue reactions18.
Dose uncertainties during treatment planning contribute to discrepancies in dose
delivery that might lead to underdosage of the tumor and overexposure of surrounding
healthy tissue. According to the ICRU, the overall uncertainty in the delivered dose
to the patient should not be greater than 5%19;20. A further analysis of uncertainties
associated with radiation treatment shows that this would require the accuracy for the
2RBE is defined as the ratio of a dose of a reference radiation quality (usually photons) to a dose
of a test radiation (such as protons or carbon ions) to produce the same biological effect9.
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dose calculation algorithm alone to be on the order of 2%-3%. This accuracy level is
generally achievable with modern TPS in water-equivalent phantoms. However, it can
be verified only for a limited set of dosimetric tests, normally performed during system
commissioning and as a part of a quality assurance program. Owing to the complexity
of patient heterogeneities combined with a broad range of external beam treatment
conditions, slightly larger errors might be expected in three-dimensional patient dose
distributions.
1.4 Coping with tissue heterogeneities in the treatment
planning procedure
Radiotherapy treatment planning can be described as the procedure that, taking as
input a model of both the radiation beam and the patient anatomy—given usually by a
computed tomography (CT)—, produces as output two kinds of information: machine
instructions to deliver the treatment (such as beam energy, beam shape and number
of particles to be delivered in each beam—also known as monitor units (MU)) and the
expected dose distribution in the patient, which allows to quantify the probability of
tumor control and of complications to the normal tissues.
In the clinics, plans are usually obtained from analytical dose calculation algorithms
integrated in TPS.
1.4.1 Deficiencies of analytical dose calculations
Analytical dose calculation algorithms provide dose distributions in clinically accept-
able timescales. The computation speed lies on several approximations in the dose
calculation procedure. Dose calculations are based on water-equivalent properties and
elemental compositions of each material are disregarded. Considering that our body
is 90% water, this approach seems reasonable to a first approximation, even though
interaction of radiation with matter strongly depends on the atomic composition of the
medium. Analytical dose calculation algorithms provide reasonable accuracy in water-
like tissues but the reliability of predicted dose distributions in the patient might be
questioned when the radiation beam is traversing complex tissue heterogeneities, such
as air, lung or bone, which radically differ from water in terms of density and atomic
number (Z).
Analytical dose calculation algorithms are usually validated using Monte Carlo
(MC) simulations and experimental measurements.
1.4.2 MC simulations
MC is a powerful and accurate tool in dose computations in RT. MC simulations are
stochastic solutions to the linear Boltzmann transport equation (LBTE). The LBTE
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takes the form of the partial differential equations:
Ωˆ · ~∇Φγ + σγt Φγ = qγγ + qeγ + qγ (1.1)
Ωˆ · ~∇Φe + σetΦe −
∂
∂E
(SRΦ
e) = qee + qγe + qe (1.2)
Equation 1.1 describes photon (γ) transport and equation 1.2 describes electron (e)
transport. Φγ
(
~r,E, Ωˆ
)
and Φe
(
~r,E, Ωˆ
)
are the photon and electron angular fluence,
respectively. ~r is a position vector, E is the energy of the particle and Ωˆ is the unit
direction vector. σγt (~r,E) and σ
e
t (~r,E) are the total photon and electron cross sections,
respectively, and SR (~r,E) is the restricted collisional and radiation stopping power
representing the continuous slowing down operator. The terms on the right hand side
of equations 1.1 and 1.2 are primary and scatter source terms. qγ and qe are primary
photon and electron source terms, respectively, qγγ represents scattered photons due
to photon interactions, qee represents scattered electrons due to electron interactions,
qeγ represents scattered photon due to electron interactions and qγe represents the
reverse21.
A random number generator is used to sample the interactions experienced by a
particle in chronological succession. These interactions are stored in particle histories
and accumulated over millions of particles to obtain the exact solution to the LBTE—
apart from inherent statistical uncertainties. Thus, errors are primarily stochastic
provided that reliable physical models are considered.
Unlike analytical dose calculations, MC simulations take into account the specific
properties of each material, such as its atomic composition, electronic density or ion-
ization potential. Further, MC dose calculations distinguish explicitly between elec-
tromagnetic and nuclear interactions (non-elastic interactions and multiple scattering).
Hence, MC simulations yield highly-accurate dose distributions provided proper source
and tissue models are available22 and are taken as the benchmark in many situations in
radiotherapy13. The accuracy is also limited by the finite number of particles simulated.
The development of efficient computation code and the advances in computer pro-
cessor technology in recent years, have significantly enabled applications of the MC
method in radiation therapy23. These advances have motivated several major treat-
ment planning system vendors to embark upon the path of MC techniques. Several MC
algorithms for photon, electron and/or proton have already been released—or are cur-
rently in the process of being released. Some examples for photons and electrons are the
PEREGRINE system24, the series of codes based on the Voxel Monte Carlo (VMC)
(XVMC, VMC++)25, the dose planning method (DPM)26 or the recently developed
PRIMO27. The VMCpro, based on the VMC, was developed for treatment planning in
proton beam therapy28. Paganetti et al. 22 built a fully-MC proton dose calculation al-
gorithm to support routine treatment planning and delivery with the GEANT4 code29.
A further development of the code has culminated in a full TPS named TOPAS30;31, a
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Unfortunately, accuracy and calculation time are inversely proportional. Thus, de-
spite offering a high precision, MC-based approaches generally entail long calculation
times unaffordable in the clinical routine and are often reserved for research applica-
tions. Further, it should be born in mind the sensitivity of the MC results to the input
parameters and the choice of models. In this sense, experimental measurements might
be essential to procure real dose estimations provided a proper detector is available.
1.4.3 Experimental measurements
The commissioning of a therapeutic radiation beam requires reference dose measure-
ments to calibrate the beam monitor chambers for the MU calculation, relative dose
measurements to feed the TPS and field-specific dose distribution measurements to
validate the dose distribution predicted by the TPS.
The general problem is expressed as follows: a detector is placed in a medium
irradiated by a particle beam and yields a signal corresponding to a certain quantity of
radiation or “exposure”. The signal collected by the detector, Mdet, is proportional to
the energy deposited in it, and thus, so it is to the absorbed dose, Ddet. The step from
Mdet to Ddet at some reference conditions and radiation quality, is known as calibration.
The aim of the measurement is to determine the absorbed dose in the medium, Dm,
as of Ddet in the absence of the detector, alternatively expressed as in the undisturbed
medium. In general, the relation between Ddet and Dm is given as:
Dmed = Ddet · sdet,med · p (1.3)
where sdet,med is the stopping power ratio derived from the Spencer-Attix cavity
theory32 and p is the perturbation factor. The term perturbation is used in the sense of
a perturbation by the detector of the electron fluence present at the position of interest
P in uniform medium, Φmed(P ), where the relevant fluence in the detector, inevitably
a mean value over a finite volume, Φ¯det is that which gives rise to the signal. p is
a property of the detection material, the detector size and the radiation field. If the
detector is small compared to the ranges of the charged particles crossing the cavity
then it behaves as a Bragg-Gray detector (or a small cavity) and p is unity33—therefore,
the conversion from Ddet to Dmed relies only on sdet,med.
For multiple charged particles, the sdet,med is calculated as follows:
sdet,med =
∑
i
∫ Emax
Eicut
Φidet(E)(L∆(E)/ρ)
i
detdE+Φ
i
det(E
i
cut)(Sel(Eicut)/ρ)
i
det
Eicut∑
i
∫ Emax
Eicut
Φidet(E)(L∆(E)/ρ)
i
meddE+Φ
i
det(E
i
cut)(Sel(Eicut)/ρ)
i
med
Eicut
(1.4)
where i = {p, e, α, ...} are all the charged particles that contribute to the dose
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(a) photon beams (b) proton beams
Figure 1.8: Spencer-Attix sdet,med values as a function of depth for (a) photon beams of different
energies (adapted from reference Andreo and Brahme 39) and (b) a 150 MeV proton beam for different
detection materials (from Goma`, Andreo, and Sempau 38).
in the detector or cavity; Eicut is the cut-off energy of the i-th particle; Φ
i
det (E) is
the distribution of the fluence of the i-th particle in the detector with respect to the
energy; and (L∆/ρ)
i
med and (Sel/ρ)
i
med are the mass linear energy transfer and the mass
electronic stopping power, respectively, of the i-th particle in the medium. An upper
limit for Eicut is typically defined as the mean energy of the i-th particle with a sufficient
residual range to cross the cavity.
A set of stopping power ratios have been calculated over the years for different
detector/medium combinations32;34–38. An example of Spencer-Attix Sdet,med values
as a function of depth for different detection materials are depicted in figure 1.8 for
photon and proton beams.
According to the IAEA TRS-39840, Dw under reference conditions must be mea-
sured in water with cylindrical or plane-parallel ionization chambers (IC). Dosimetry
protocols provide a set of correction factors p for converting ionization into dose, but
only for water-equivalent materials and at a reference depth40;41. The dosimetric data
to obtain the dose in materials other than water, such as stopping power ratios and mass
energy absorption coefficients are not given in the dosimetry protocols and the pertur-
bation correction factors in combination with heterogeneous media are also unknown
for most IC types. Hence, IC can not be used for the absorbed dose determination in
media other than water if p is unknown. Recently, Araki 42 evaluated the perturbation
correction factors for a PTW31010 IC for MV photon beams in heterogeneous media.
The author reported that p was up to 6% in bone for 15 MV.
Despite being IC the detectors of reference in clinical dosimetry, other detectors—
commonly calibrated to yield dose to water—are used in the clinical routine to assess
the absorbed dose and can be useful for measurements in the presence of heterogeneities.
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Radiochromic films43 or scintillation screens, for example, are suitable for measuring
lateral dose profiles given that they offer a high spatial resolution. MOSFET detectors
are especially useful for in vivo dosimetry or high-dose gradient fields44. Yet they are
not very common in the clinical practice, thermoluminescent dosimeters (TLDs)45 have
several advantages. Their small size (usually ≈ 1 mm-thick) makes them potentially
good candidates for generating a low fluence perturbation factor p in MV beams—the
smaller the size of the detector the lower the perturbation factor46;47, as mentioned
above. In particular, ultra-thin TLDs48 (active layer thickness < 100µm)—unmatched
for personal dosimetry—might be of interest in this context. Ultra-thin TLDs have
been used for the dose assessment in regions of steep dose gradient, such as for skin
dose measurements in high-energy photon treatments49–51.
1.5 On the verification of dose calculation algorithms in
heterogeneous media: a state of the art
The effect of heterogeneities on dose distributions mentioned in section 1.4.1 is an is-
sue that has concerned the medical physics community for almost three decades and
it is still a topic of major concern. In the literature one can find different algorithms
for dose calculation used in radiotherapy treatment planning, and their fundamentals
are described in great detail by Ahnesjo¨ and Aspradakis 52 , and by Papanikolaou and
Stathakis 53 in a more recent study. These algorithms are based on calculations of pri-
mary photon beam attenuation and dose-deposition kernels3 in water52. When using
these algorithms in media other than water, a heterogeneity correction is used. Hetero-
geneity corrections performed to non-water materials have evolved with (i) computing
speed and (ii) the understanding and modeling of the radiation transport through re-
gions of varying density. All the algorithms have a heterogeneity pathlength correction
based on the mass-density of the medium. This correction is known as the equivalent
pathlength (EPL). The EPL method scales the beam dose distribution to take into
account changes with depth of the primary fluence in a medium different than water.
Broadly speaking, dose calculation algorithms implemented in commercial TPS can
be classified into two main groups:
• Group 1. Models primarily based on EPL for inhomogeneity corrections where (i)
the electron transport is not separately modeled, and (ii) the density changes are
sampled along the 1D primary rays. Pencil-beam convolution (PB) algorithms
and the fast Fourier convolution algorithm (FFTC) belong to this group.
• Group 2. Models capable of treating the electron transport in an approximate
3A dose kernels a matrix that represents dose deposition by scattered photons and electrons gener-
ated by the initial interactions of primary photons. The kernel can be generated by measurement or
by a modeling system.
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way and the secondary photon transport in the medium accounting for density
changes, sampled along the full three dimensions. The collapsed cone (CC) algo-
rithm, the anisotropic analytical algorithm (AAA) and the multigrid superposi-
tion/convolution (MGS-XiO) belong to this group of “advanced” models.
A broad discussion on some of the aforementioned algorithms was done by Kno¨o¨s
et al. 54 .
Up to now, many studies have been published on the dosimetric validation of dose
calculation algorithms, both for photon and for proton therapy fields. MC methods and
experimental measurements have been applied in the verification procedure. Before go-
ing into further details it is known that conventional dose calculation algorithms that
convolute invariant kernels derived from measurements in water underpredict/overpre-
dict the dose inside high-density/low-density materials for high-energy x-ray and proton
beams. This underprediction/overprediction is due to the fact that the TPS do not
model the increase/decrease of the interaction coefficient inside the bone/lung and only
account for the decreased/increased transmission caused by the higher/lower density
material55.
1.5.1 On photon dose calculation algorithms
Over the years a large number of groups have explored the ability of different al-
gorithms to manage the presence of materials different from water when computing
three-dimensional dose distributions in slab phantoms53;54;56–61. The MGS and the
FFTC algorithms have been validated against measurement with radiographic films
and ion chambers62. Concerning CC, it has been extensively tested by several groups
in various geometries against MC simulations55;63. Fogliata et al. 58 investigated the
performance of most of the dose calculation algorithms mentioned in section 1.4 in non-
homogeneous phantoms. They confirmed the inadequacy of the algorithms belonging
to the first group defined in section 1.4, especially for small fields in low density media.
For the tested algorithms belonging to the second group, their results depended on the
beam energy, field size and density investigated.
Most studies to date have investigated low-density materials equivalent to lung55;62–67,
and some have studied high-Z materials, such as those that compose hip prothesis68
or bone structures69;70. One of the causes of this imbalance is that lung injury appears
at doses as low as 20 Gy71, whereas bone reactions appear at higher doses in stan-
dard fractionated radiotherapy. Consequently, the misevaluation of the dose inside the
lung has been a cause of concern since the early days of radiotherapy. At the present
moment, misevaluation of the dose inside the bone could also be a problem in dose
escalation studies, where very high doses are being delivered.
Although most of the effects in bone can be understood to be the opposite of those
occurring in lung, the following three do not have a corresponding effect:
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1. backscatter at the interface between water and bone,
2. the re-buildup in the interface between bone and water, and
3. the spectral change of the beam after the bone.
The first two are interface effects and they have been studied and reported72. The
re-buildup after the interface between bone and water is a phenomenon that is less
known than backscatter, and it is due to the different characteristics of the electrons
generating in bone and those originating from the water close to the interface. In the
water-equivalent part of the phantom, the number of electrons originating from bone
decreases with depth while the number of electrons originating in water increases. The
two effects are not mutually compensating, as electrons generated from bone would
undergo wider-angle scattering in a higher Z material and would be ejected from the
bone in a more isotropic manner. This difference generates a buildup of dose. The
third effect, is observed for certain MV energies as Z increases, because of the increase
in the pair production cross section73. None of these effects are taken into account by
correction-based algorithms yet they might be significant.
Varian Medical Systems developed a non-analytical dose calculation algorithm that
directly solves the LBTE iteratively named Acuros XB (AXB). A preclinical version
was evaluated by Vassiliev et al. 21 in 2010 showing encouraging results in predicting the
dose distributions in the presence of high-density and low-density tissue heterogeneities.
Since then, a few studies have been published on the verification of this algorithm using
either MC simulations or experimental measurements. In general, AXB has been found
to be able to provide comparable accuracy to MC in clinically-acceptable computation
times. However, there is still room for further investigation on the special features of
the algorithm. Further discussion will be made on the state of the art regarding the
validation of AXB in chapter 5.
1.5.2 On proton dose calculation algorithms
As it has been shown by several authors, the effect of multiple Coulomb scattering
causes the degradation of the Bragg peak when a proton beam traverses complex inho-
mogeneous media74–77 as shown in figure 1.9—in the absence of scattering, the inho-
mogeneities would simply shift the range of protons. This causes substantial changes
in the energy spectrum of the proton fluence and therefore, in the distal fall-off width.
Some studies have focused on the development of analytical models to estimate range
dilution of the Bragg peak in the presence of heterogeneities78.
PB algorithms commonly use a one-dimensional dose-scaling method of a proton
pencil beam in water. Pflugfelder et al. 79 highlighted the deficiencies of a pencil beam
algorithm for scanned proton beams when these were traversing a highly heterogeneous
region in the patient. The suppression of those pencil beams going through highly
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Figure 1.9: Degradation of the Bragg peak due to inhomogeneities. From Lomax 16 .
inhomogeneous regions resulted in more robust plans. In a recent study, Yamashita
et al. 80 reported significant differences between pencil beam dose calculations and MC
in the distal fall-off of the SOBP and in the planning target volume coverage for a set
of patients and tumor sites, owing to the presence of heterogeneities within the beam
path.
Paganetti et al. 22 compared the dose distributions predicted by a PB algorithm81
against MC simulations for a set of patients. In most of the studied cases, they found
differences in proton ranges4. These differences depended on the range compensator
gradient, the amount of bony anatomy in the beam path (large density variations)
and the existence of air-bone-tissue interfaces—in particular if those interfaces were
tangential to the beam.
Bednarz, Daartz, and Paganetti 82 presented the dosimetric limitations of the same
algorithm for predicting hot and cold spots and range degradations in the target due
to scattering in heterogeneities. Comparisons were done against MC simulations for
small proton fields involved in stereotactic and fractionated radiotherapy treatments.
Discrepancies up to 8.6% were found for one of the fields.
1.6 Absorbed dose comparisons
As mentioned in previous sections, a full comparison between dose calculation algo-
rithms, MC simulations and experimental measurements is usually performed for ver-
ification purposes. An important feature which has not been addressed yet in this
dissertation is that different clinical calculation methods may yield different quantities
related to the absorbed dose for a given tissue. While MC simulations yield the dose
to the tissue or medium itself, Dm, traditional correction-based calculation algorithms
give the dose to a small water cavity within the tissue, Dw. However, modern convo-
lution/superposition algorithms report Dm as they re-scale the interaction kernels in
the traversed media. On the other hand, detectors are commonly calibrated to yield
Dw. The conversion from one another is done by using the stopping power ratios as
4The range of a particle is known as the distance the particle travels until it has released almost all
of its energy to the medium.
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expressed in equation 1.4.
Several studies comparing Dm to Dw have been conducted up to now. For soft
tissue the differences may be in the order of 1-2% whereas for higher density materi-
als, such as cortical bone, the differences can be as large as 15%36. Dogan, Siebers,
and Keall 83 retrieved large deviations—up to 8%—between Dm and Dw for head and
neck and prostate IMRT plans, especially when bony structures were involved in the
target volume. Walters, Kramer, and Kawrakow 84 found clinically significant differ-
ences (above 5%) between Dm and Dw in the cranium spongiosa, where the volume
fraction of trabecular bone is high. A study on the approach to accurately convert the
information of the MC results to Dw for proton beams—to allow comparisons against
TPS—has been performed by Paganetti85.
The question of which quantity should be adopted for comparison purposes is still
under debate, as discussed by Liu and Keall 86 or Dogan, Siebers, and Keall 83 . There
are strong arguments that support the use of both, Dm or Dw. Arguments in favor
of changing to Dm-based protocols include: (i) the conversion from the MC-Dm to
Dw adds an additional level of uncertainty due to uncertainties in computed stopping
power ratios; (ii) Dm is more likely to provide a better measure of biological response;
and (iii) changing to Dm will not have a clinically significant impact on most treatment
protocols, since most tissues of interest are similar to water.
On the other hand, those who advocate for the usage of Dw argue that (i) all
clinical experience and current dosimetry protocols are Dw-based
85; (ii) clinical ex-
perience in terms of tumor/tissue response is based on Dw; and (iii) radiosensitive
structures within cells are water-equivalent and may thus be modeled as a water cav-
ity within the medium. Another reason that favors the latter position is that there is
uncertainty in the medium type and composition when converting from CT numbers
to media, potentially making the “medium” in Dm unknown
36;86;87. Schneider, Bort-
feld, and Schlegel 88 suggested an accurately method for a stoichiometric calibration of
CT numbers with tissue parameters which is used in many MC algorithms for patient
dose calculations. However, the calibration curve used in the clinics for converting CT
numbers to electron density or relative stopping power, for photon and proton beams
respectively, is CT scanner-dependent and therefore it is always a source of discrepancy
between the treatment planning and the MC simulation.
Anyhow, what is beyond the shadow of a doubt is that dose distributions to be
compared must be consistent with each other.
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Chapter 2
Aim and Outline
The presence of tissue heterogeneities within the beam path might question the reli-
ability of dose distributions predicted by treatment planning systems (TPS) based on
analytical dose calculations. This issue has concerned the medical physics community
for three decades and it is still a matter of concern.
Monte Carlo (MC)-methods can yield highly accurate dose distributions and are
commonly considered the benchmark for dose calculations in radiotherapy. However,
the large demand in computing time is still currently prohibitive for routine use of MC
in treatment plan optimization, especially when considering highly-conformal modern
delivery techniques.
In this context, Acuros XB (AXB), a deterministic Boltzmann-solver dose calcula-
tion algorithm, was recently presented as a powerful alternative to MC simulations for
dose calculations in photon therapy treatments. Some studies on the dosimetric verifica-
tion of the algorithm have proved the ability of AXB to provide comparable accuracy to
MC even in inhomogeneous media. However, there is still room for further investigation
on the features of the algorithm. No analogous dose calculation algorithm to AXB is
currently available for proton beams, yet dose uncertainties during treatment planning
might have detrimental consequences on the tumor coverage and organs-at-risk sparing.
On the other hand, the experimental determination of the absorbed dose is funda-
mental in the validation of the MC computations in reference conditions and in the
verification of TPS in the clinical routine—where MC methods might not be avail-
able. It must be taken into account that both MC and TPS dose calculations might
be affected by similar sources of uncertainty, such as those arising from the materials’
definition (atomic composition, mean excitation energy). In this sense, experimen-
tal measurements might be essential to procure real dose estimations provided that a
proper detector is available. Current dosimetry protocols for external beam radiother-
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apy based on absorbed dose to water standards (ADWS) establish the determination of
absorbed dose to water (Dw) in reference conditions using an ionization chamber (IC),
but the correction factors for most IC in other media/tissues are unknown.
According to what is mentioned above, the goal of this thesis is:
to contribute to solve the current issues on the accurate absorbed dose determina-
tion in the presence of tissue heterogeneities for both photon and proton radiotherapy.
To this end, this work tackles the problem of the dose assessment in such conditions
by (i) analytical algorithms, (ii) MC methods and (iii) experimental measurements.
This thesis has been developed in collaboration with several catalan hospitals and a
foreign institution:
Hospital de la Santa Creu i de Sant Pau (HSCSP), Barcelona, Spain.
Hospital Duran i Reynals—Institut Catala` d’Oncologia (ICOB), Barcelona, Spain.
Hospital Josep Trueta—Institut Catala` d’Oncologia (ICOG), Girona, Spain.
Massachusetts General Hospital and Harvard Medical School (MGH), Boston,
USA (from February 2011 until October 2011).
The outline of this thesis is divided in four sections (objectives) gathered in four
chapters in this manuscript (chapters 3-6). The tasks of each section are detailed below:
I: Obtaining of reliable MC simulations for photon and proton beams
• Geometry construction, optimization and beam commissioning in reference con-
ditions of a Varian Clinac 2100 C/D accelerator head for MV photon beams with
the PENELOPE code in combination with penEasy as the main program.
• Usage of the TOPAS platform for the simulation of an IBA proton nozzle for
dose calculations in patients. Geometry construction and code commissioning
had been previously carried out by the TOPAS collaboration group.
These tasks are described in chapter 3. The generated MC beams are a transversal
dosimetric tool and were subsequently used for several applications in chapters 4-6.
II: Analysis of the capability of several type of ultra-thin thermoluminescent
detectors (TLDs) and radiochromic films to provide reliable absorbed dose
measurements for radiotherapy beams in the presence of heterogeneities
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• Dosimetric characterization of the detectors for radiotherapy fields: energy de-
pendence and linearity with dose were evaluated for a wide range of beam con-
figurations.
• Experimental measurements in phantoms with bone-equivalent heterogeneities.
• Evaluation of the detectors’ perturbation effects using MC.
The evaluation of the responses of TLDs and films is described—together with the
obtaining of the MC beams—in chapter 3. This provides the basis for the development
of the following mentioned tasks, described in chapter 4.
III: Evaluation of the behavior of AXB in the presence of heterogeneities
• Basic verification of the AXB dose accuracy in water.
• Experimental (TLDs and radiochromic films) and MC validation of the algorithm
in phantoms with lung-equivalent and bone-equivalent heterogeneities.
• Analysis of the effect of HU fluctuations and material assignments in the final
dose distributions.
This section is developed entirely in chapter 5. The generated MC photon beams
and the dosimeters characterized previously were used herein.
IV: Definition of an indicator for the accuracy of dose delivery based on
analytical dose calculations to identify those patients for which MC dose
calculation is recommended.
• Development of a fast and easy-to-calculate algorithm—named the heterogeneity
index (HI)—to quantify the lateral tissue heterogeneities within a patient tra-
versed by a single radiotherapy beam.
• Obtaining of HI-values for several small passively-scattered proton fields involved
in the treatment of a set of patients.
• Evaluation of the differences between the dose distributions predicted by an an-
alytical dose calculation algorithm and those calculated by MC using TOPAS.
• Study of the potential correlation between the dose differences and the HI-values
for all considered fields in order to be able to determine the cases for which MC
should be considered to keep the dose uncertainties below the tolerance levels.
Chapter 6 is devoted to describe these tasks. The generated MC proton beams were
used herein to verify the dose derived from the TPS.
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Chapter 3
Multipurpose dosimetric tools
This chapter gathers the development and start-up of the dosimetric tools—Monte
Carlo (MC) beams and detectors’ characterization, described in chapter 2—in order to
carry out the following tasks involved in this thesis work. Unless explicitly stated, the
work has been done by the author of this thesis work.
3.1 Generation of MC beams
3.1.1 Obtaining of the megavoltage photon source
3.1.1.1 The photon MC code
The code PENELOPE89;90, an acronym of PENetration and Energy LOss of Positrons
and Electrons in matter, was used for the MC photon dose calculations. PENELOPE
was developed at the Universitat de Barcelona and it is distributed by the Nuclear
Energy Agency (NEA). It is coded in Fortran90 and it is free and open source. PENE-
LOPE simulates the coupled transport of photons, electrons and positrons in the energy
range from 50 eV to 1 GeV, and in arbitrary material.
The simulation of photon transport follows the usual analogue procedure, i.e. all
the interaction events in a photon history are simulated in chronological succession
until the photon reaches an energy lower than a user-defined threshold (the absorption
energy, Eabs). Many-body and aggregation effects are ignored and atoms are regarded
as independent. The simulation of electron and positron tracks is performed by means
of a mixed algorithm. Individual “hard” elastic collisions (deflections larger than a
given cut-off angle), “hard” inelastic interactions (energy loss larger than a given cut-
off, WCC) and “hard” bremsstrahlung emission (energy loss larger than a given cut-off,
WCR) are simulated by random sampling from the corresponding restricted differential
cross sections. Energy straggling for inelastic and bremsstrahlung interactions is ac-
counted for in a consistent manner. Thus, electron step size is selectable by means
of user-defined parameters: WCC, WCR are mentioned above; C1 is the average angular
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deflection; C2 is the maximum average energy loss; and dsmax is the maximum allowed
step length. Analogue collision-by-collision electron/positron simulation is performed
by setting C1 = C2 = WCC = 0.
The track of a particle between successive hard interactions or between a hard
interaction and the crossing of an interface (i.e. a surface that separates two media
with different compositions) is generated as a series of steps of limited length. The
combined effect of all (usually many) soft interactions that occur along a step is simu-
lated as a single “artificial” soft event (a random hinge) where the particle loses energy
and changes its direction of motion. The energy loss and angular deflection at the
hinge are generated according to a multiple scattering approach that yields energy
loss distributions and angular distributions with the correct mean and variance (first
and second moments). Secondary particles emitted with initial energy larger than
the absorption energy (Monte Carlo transport cut-off) are stored, and simulated after
completion of each primary track. Secondary particles are produced in direct inter-
actions (hard inelastic collisions, hard bremsstrahlung emission, positron annihilation,
Compton scattering, photoelectric absorption and pair production) and as fluorescent
radiation (characteristic x-rays and Auger electrons).
PENELOPE users can adapt a steering main program in order to define the radia-
tion source, the simulation parameters, the quantities of interest to be scored, variance-
reduction (VR) techniques to be applied and report the final results. The modular
general-purpose main program for PENELOPE named penEasy91 has been employed
in this thesis. It was developed at the Institut de Te`cniques Energe`tiques (Universitat
Polite`cnica de Catalunya) and it is both free and open source. The input file for the
executable is a simple text.
3.1.1.2 Geometry construction
In PENELOPE, the geometry construction consists of a number of homogeneous bodies
defined by their composition (material) and limiting quadric surfaces. In the context
of this thesis a Varian Clinac 2100 C/D was simulated for two photon beam energies:
6 and 18 MV. This work is a refinement of older modelizations of the accelerator head
performed by the group and includes the last updates on the dimensions of the primary
collimator given by Chibani and Ma 92 for the 18 MV configuration. The elements of
the accelerator head (schematized in figure 1.4) were built according to manufacturer
specifications.
The geometry for the 6 MV beam consisted of 48 modules and 74 quadric surfaces.
For the 18 MV, a total number of 149 modules and 198 surfaces were used. The
difference in number lies basically on the flattening filter construction, which has a
much complicated shape in the case of the 18 MV source.
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Beam Energy Mean e− energy Energy (E) spread (MeV) Radial intensity (cm)
(MV) (MeV) (FWHM of Gaussian (FWHM of Gaussian
E distribution) x, y distribution)
6 6.20 0 0.15, 0.15
18 18.0 1 0.20, 0.20
Table 3.1: Electron (e−) beam parameters for the commissioning of 6 and 18 MV photon beams.
3.1.1.3 Photon beam commissioning
Small variations of the initial electron beam parameters might strongly influence the
dose distributions in the patients. There are many studies in the bibliography93–98 that
have reported the influence of: (i) the mean energy of the electron beam hitting the
target, (ii) its energy spread (which is usually taken as a Gaussian distribution), (ii) its
radial intensity and (iii) its angle of incidence, and they are summarized by the AAPM
Task Group 10523.
From this publications, several conclusions can be reached. First, the radial in-
tensity of the electron beam does not affect the depth-dose curves for the depth past
maximum; variations of this parameter from 0.0 cm (pencil beam) up to 0.4 cm produce
local differences on the depth-dose curves below 1% (see for example Tzedakis et al. 94).
On the contrary, the radial intensity of the electron beam affects the dose-profile curves
considerably for large field sizes—for smaller fields, its influence is negligible. The mean
energy affects both dose-profiles and depth-dose curves. Nevertheless, the effect is more
visible in dose-profiles for large field sizes. Finally, the energy spread is found to have
no influence either on depth-dose or on dose-profile curves.
The electron beam parameters were adjusted with a trial and error method, to
match the measured data. Percent depth-dose (PDD) curves and lateral dose profiles at
the depth of dose maximum were measured in a water phantom of 50×50×50 cm3 using
0.35 cm3 Roos ionization chamber (IC) (PTW, Freiburg, Germany) and Scanditronix
PFD-3G diode, respectively, for both beam energies (6 and 18 MV) and a field size of
10× 10 cm2. The final beam parameters are listed in table 3.1.
After adjusting the field of reference, PDDs and lateral profiles were validated
against experimental measurements for field sizes between 2 × 2 cm2 to 20 × 20 cm2.
PDDs were measured in water using 0.35 cm3 Roos IC for the largest fields (10×10 cm2
and 20× 20 cm2), and 0.016 cm3 PinPoint 31016 IC (PTW Freiburg, Germany) for the
smallest fields (2 × 2 cm2 and 5 × 5 cm2). Dose profiles were measured in water with
Scanditronix PFD-3G diode. The results are depicted in figures 3.1-3.2 and 3.3-3.4 for
6 and 18 MV, respectively.
Deviations between simulated PDD curves and measurements for the set of stud-
ied energies and field sizes were below 1.2% in all cases. Discrepancies in beam
penumbrae—defined as the distance between the 80% and the 20% of the central axis
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Figure 3.1: PDD curves normalized to the depth of dose maximum (1.5 cm) (i) calculated with
Monte Carlo (MC) and (ii) measured experimentally (EXP) in water for the 6 MV photon beam.
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Figure 3.2: Lateral dose profiles at the depth of dose maximum (1.5 cm) (i) calculated with Monte
Carlo (MC) and (ii) measured experimentally (EXP) in water for the 6 MV photon beam, normalized
to the central axis value.
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Figure 3.3: PDD curves normalized to the depth of dose maximum (3.3 cm) (i) calculated with
Monte Carlo (MC) and (ii) measured experimentally (EXP) in water for the 18 MV photon beam.
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Figure 3.4: Lateral dose profiles at the depth of dose maximum (3.3 cm) (i) calculated with Monte
Carlo (MC) and (ii) measured experimentally (EXP) in water for the 18 MV photon beam, normalized
to the central axis value.
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dose—were within 0.4 mm for all beam configurations.
3.1.1.4 Simulation in two steps
Simulations were done in two steps: first particles were tracked through the accelerator
head and stopped on a plane after the secondary collimators or jaws (see figure 1.4); the
particle type, energy, position and momentum are stored in a phase-space file (PSF).
Then, the PSF was used as the particle source for the dose distribution calculation on
the patient/phantom99. This enables the re-usage of the same PSF in order to improve
the statistical uncertainty of the final dose computation.
3.1.2 Variance reduction techniques
A very important concept in MC simulations that will be referred throughout this
manuscript is the efficiency () of the simulation. It can be defined as follows:
 =
1
t∆2
(3.1)
where t is the execution time and ∆ is a measurement of the uncertainty of the
magnitude of interest.
An intrinsic efficiency would be defined as:
N =
1
N∆2
(3.2)
where N is the number of histories1. This magnitude depends on the algorithm ex-
clusively. Combining both expressions 3.1 and 3.2, the total efficiency can be expressed
as:
 = N
N
t
(3.3)
which depends on the simulation speed (N/t, histories per second), which at the same
time depends on the CPU/GPU and the compiler.
In order to speed-up the simulations and therefore improve the efficiency, the appli-
cation of variance reduction (VR) techniques is strongly recommended100. The most
popular techniques are (i) interaction forcing, (ii) Russian Roulette and (iii) particle
Splitting. These techniques have been applied by many authors for the MC simulation
of accelerator heads101–103. Their main features can be summarized as follows:
3.1.2.0.1 Interaction forcing. Sometimes, high uncertainties result from an ex-
tremely low interaction probability. In such cases, an efficient variance-reduction method
is to artificially increase the interaction probability of the process A of interest, i.e. to
1A history is defined in this context as the process that involves the simulation of a primary particle
and all secondary particles derived from it.
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force interactions of type A to occur more frequently than for the real process. The
practical implementation of interaction forcing consists of replacing the mean free path
λA of the real process by a shorter one, λA,f . This is equivalent to increasing the
interaction probability per unit path length of the process A by a factor
F =
λA
λA,f
> 1. (3.4)
To keep the simulation unbiased, we must correct for the introduced distortion as
follows: a weight ω = 1 is associated with each primary particle. Secondary particles
produced in forced interactions of a particle with weight ω, are given a weight ωs = ω/F.
Secondary particles generated in non-forced interactions (i.e. of types other than A)
are given a weight equal to that of their parent particle.
Interaction forcing was applied in the target of the accelerator head to enhance the
production of bremsstrahlung x-rays. Factors F=30 and F=100 were found to be the
most efficient for 6 and 18 MV, respectively, in terms of number of particles stored in
the phase-space plane per second. An F-value too large might slow down the simulation
speed by generating particles that will never contribute to the PSF. This technique was
used in combination with others, as detailed below.
3.1.2.0.2 Russian roulette and Splitting. These two techniques, which are
normally used in conjunction, are effective in problems where interest is focused on a
localized spatial region. The basic idea of splitting and Russian roulette methods is
to favor the flux of radiation towards the region of interest and inhibit the radiation
that leaves that region. As in the case of interaction forcing, variance reduction is
accomplished by modifying the weights of the particles. In a normal situation, it is
assumed that primary particles start moving with unit weight and each secondary
particle produced by a primary one is assigned an initial weight equal to that of the
primary. Splitting consists of transforming a particle, with weight ω0 and in a certain
state, into a number S > 1 of identical particles with weights ω = ω0/S in the same
state. Splitting should be applied when the particle “approaches” the region of interest.
The Russian roulette technique is, in a way, the reverse process: when a particle tends
to move away from the region of interest it is “killed” with a certain probability, K < 1,
and, if it survives, its weight is increased by a factor 1/ (1−K). Here, killing means
that the particle is just discarded (and does not contribute to the scores anymore).
Evidently, splitting and killing leave the simulation unbiased. The effectiveness of
these methods relies on the adopted values of the parameters S and K, and on the
strategy used to decide when splitting and killing are to be applied. These details can
only be dictated by the user’s experience.
Rotational splitting101 was carried on in a plane right before the accelerator’s jaws.
Other geometry-related techniques, such as the use of “skins”, were used as described
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elsewhere102;103.
3.1.3 Obtaining of the proton source
3.1.3.1 The proton MC code
TOPAS30;31, a TOol for PArticle Simulations, was used for the MC proton dose cal-
culations. TOPAS has been developed under a collaborative project between the Mas-
sachusetts General Hospital (MGH) (Harvard Medical School, Boston, US) together
with the SLAC National Laboratory (Stanford University, California, US). TOPAS in-
corporates the already-proven Geant4104 simulation toolkit into a comprehensive archi-
tecture for treatment delivery system simulations and patient calculations. Treatment
head geometry, patient handling, imaging and scoring are both flexible and easy to
use. It is a user-friendly framework based on simple text control files. Users import
DICOM, perform automatic HU conversion, use pre-defined components (range mod-
ifier wheels, propellers, steering magnets, jaws, etc.), adjust components or add new
components. TOPAS handles time-dependence such as component motion and beam
current modulation.
3.1.3.2 Geometry construction
The MC simulation of the treatment head (also named nozzle) was based on the infor-
mation provided by the manufacturer (Ion Beam Applications SA (IBA) Louvain-la-
Neuve, Belgium). Figure 3.5 shows a schematic view of the geometry of the nozzle at
MGH generated by TOPAS.
The physics settings are extensively discussed and described elsewhere22;105.
3.1.3.3 Proton beam commissioning
Paganetti et al. 106 in 2004 used Geant4 to shape the proton beam at MGH and it
was subsequently included in the recently-developed TOPAS. The authors tested the
influence of the incident proton energy, energy spread, beam spot size and beam angular
distribution. The commissioning was based on a set of measured pristine Bragg curves.
The most critical parameter was found to be the energy spread, since it influenced the
width of the Bragg peak, the slope of the distal fall-off and the peak-to-plateau ratio.
The accuracy of TOPAS has been previously validated at MGH against experi-
mental measurements in a variety of homogeneous and inhomogeneous phantoms107.
TOPAS depth-dose curves were found to be within clinical required accuracy, the range
being within +1/−1.5 mm and the modulation width within ±3 mm of the clinical spec-
ifications. The field flatness of simulated proton dose distributions was within ±2% of
the average dose measured in a plane transverse to the beam axis.
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Figure 3.5: Nozzle at MGH in TOPAS.
Figure 3.6: Main components of a passive-scattering proton nozzle.
3.1.3.4 Simulation in two steps
Unlike for photons, in proton therapy it is more difficult to split the calculation into
a patient-independent part and a patient-specific part. The main components of a
passive-scattering nozzle are schematized in figure 3.6.
The range-modulator wheel—that determines the shape of the SOBP (see figure
1.6)—, the aperture—that provides lateral conformality—, and the range compensator—
that provides distal conformality (see section 1.2.2 for more information), are beam-
specific. Then, the number of treatment options, and therefore the number of phase-
spaces which would have to be precalculated, make the generation of a look-up database
impractical. Nevertheless, the simulation is still usually split in two to allow the pos-
sibility to re-use the phase-space file several times to reduce statistical uncertainties in
the final dose calculation.
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3.1.3.5 Variance reduction techniques
VR techniques were implemented in TOPAS to reduce computation time and statistical
uncertainties. Detailed information can be found in Ramos-Me´ndez et al. 108 .
3.2 Characterization of detectors
3.2.1 Ultra-thin thermoluminescent detectors (TLD)
The most popular lithium fluoride-based (LiF) TLDs are LiF:Mg,Cu,P and LiF:Mg,Ti,
also termed as MCP and MT, respectively. Three different ultra-thin TLDs were con-
sidered: two MCP-based TL detectors (MCP-Ns48, TLD Poland and TLD-2000F109,
Conqueror Electronics Technology Co. Ltd., Beijing, China) and a 7Li-enriched MT-
based dosimeter (MTS-7s, TLD Poland).
MCP-Ns and MTS-7s are in the form of circular pellets of diameter 4.5 mm. Each
pellet consists of two layers: a thin radiation sensitive part bonded to a thick base
made of not activated LiF to which 2% of graphite was added in order to suppress
any spurious luminescence. The thickness of the sensitive layer is about 8.5 mg · cm2
(≈ 50µm), as shown in figure 3.7. The overall thickness of the pellets is 0.933±0.008 mm
and 0.877 ± 0.003 mm (1 SD) for MCP-Ns and MTS-7s, respectively. The density is
ρMCP = 2.34 ± 0.02 g/cm3 and ρMT = 2.41 ± 0.01g/cm3 (1 SD) for MCP-Ns and
MTS-7s, respectively.
TLD-2000F are 5 mg/cm2-thick circular films of phosphor powder (approximately
20µm) fixed on a polyamide tape with silicon adhesive (approximately 25µm) with a
diameter of 4.5 mm110.
MCP-Ns and TLD-2000F were microscopically analyzed on a focusing ion beam-
scanning electron microscope (FIB-SEM) (Crossbeamr Neon40 Carl Zeiss) in combi-
nation with the software analySIS 5.0 (Olympus Soft Imaging Solutions GmbH). The
images are depicted in figure 3.7.
The thermoluminescence was measured in a semiautomatic Harshaw 5500 reader
(Thermo-Electron) and the annealing was performed in a PTW TLDO oven, for all
types of TL dosimeters. The readout was always performed within 24 hours after the
irradiation.
The MCP-Ns anneal cycle was set at a nominal peak temperature of 240oC for 10
min followed by a fast quench on an aluminium block. The readout was carried out in
a two-step heating cycle: a preheat process at a temperature of 160oC for 10 s, and a
reading phase of 20 s up to 250oC with a linear heating rate of 8oC · s−1.
The MTS-7s dosimeters were annealed for 1 h at 400oC followed by 2 h at 100oC.
In this case, readout cycle was as follows: 10 s of preheat at a constant temperature
of 135oC and 16 s of light acquisition at a heating rate of 15oC · s−1 to a maximum
temperature of 310oC.
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(a) (b)
Figure 3.7: Microscopical view of MCP-Ns and TLD-2000F thermoluminescent detectors.
As for MCP-Ns, anneal cycle for TLD-2000F was set at a nominal temperature
of 240oC during 10 min followed by a quench on an aluminium block. The readout
consisted of a preheat process at a temperature of 160oC during 10 s followed by a
reading phase where detectors were heated up to 250oC at 4oC · s−1.
3.2.1.1 Individual calibration factors
Detectors were calibrated in a 137Cs beta source at the secondary standard laboratory of
the Institute of Energy Technologies (Barcelona, Spain) to obtain individual calibration
factors (CFi): CFi = X¯/Xi, where Xi is the light output from dosimeter i and X¯ is
the mean light output of all the dosimeters in the batch. Detectors were subjected to
several cycles of annealing, irradiation and readout in a preliminary study of stability
and repeatability of the batch. Only the dosimeters that kept their CFi between 0.9 and
1.1 (variations of ±10% over the mean) were considered; the others were disregarded
from this study. After selecting the final group, detectors were calibrated several times
in different days to ensure the stability of the batch.
MTS-7s exhibited the lowest sensitivity, which is in good agreement with other
studies111–113.
3.2.1.2 Characterization
Characterization of TLDs is required for accurate dosimetry, i.e. the sensitivity of the
thermoluminescent (TL) material, the energy and dose responses, the stability and
reproducibility of results, and thermal fading114–116 of the detector must be evalu-
ated for a given kind of ionizing radiation. MCP and MT dosimeters of standard
thicknesses from different manufacturers have been tested along the past years to
low-energy x and gamma rays117–119, conventional megavoltage (MV) photon47;120–122
and electron47;123–126 beams, neutrons127;128, alpha particles129, beta electrons, mixed
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fields127;130–134 and high-energy particle beams (i.e. protons and ions)135. Up to now,
no studies on the characterization of ultra-thin TLDs for therapeutic beams have been
published. In this work we analyze the ultra-thin MCP- and MT-based TLDs behavior
for MV photon and electron beams.
MCP-Ns, MTS-7s and TLD-2000F were evaluated for x-ray and electron beams from
a Varian linac 2100 C/D and a Varian TrueBeam with Flattening-Filter-Free (FFF)
mode (Varian, Palo Alto) at ICOB. The nominal energies selected were 6, 6FFF, 10,
10FFF 15 and 18 MV for the x-ray beams, and 6, 9, 12, 16 and 20 MeV for the elec-
trons. We tested (i) the energy response for the specified beams and (ii) the linearity
within the absorbed dose range from 0.2 up to 20 Gy for the photon beams. The re-
sponse of the detectors was compared to the dose measured with a trazable 0.35 cm3
Roos ionization chamber (IC) (PTW, Freiburg, Germany) connected to a UNIDOS
electrometer (Freiburg, Germany)International Atomic Energy Agency 40 placed at the
same depth than the TL dosimeter. The dose range widely covers the values typi-
cally used for patient treatments, both in conventional radiotherapy—where the dose
per fraction ranges between 1.8-3 Gy—and in stereotactic treatments—where dose per
fraction may be of several tens of Grays. A 10 cm by 10 cm field size was set and the
TLDs were irradiated in a Plastic WaterTM phantom of 30× 30× 20 cm3, at a depth of
10 cm for the x-ray beams and at the depth of maximum dose when irradiating with the
electron beams40. We applied the CFi to each dosimeter readout. In order to decrease
the standard deviation (σ) of the results, nine detectors were used simultaneously in
each irradiation.
Figure 3.8 shows the energy response of TLD-2000F, MCP- Ns and MTS-7s for the
photon and electron beams selected. The results are relative (in percentage) to the 6
MV x-ray beam for photons and 6 MeV for electrons. Measurements were obtained
within a 2.2% statistical uncertainty in all cases.
All detectors showed no significant energy dependence for the filtered MV photon
and electron beams selected (variations within 2.5%), which is in good agreement with
other publications on MCP- and MT-based TLDs121. The energy dependence of the
detectors was also kept within the tolerance (2.5%) for the non-filtered photon beams.
This is the first study to show the behavior of TLDs for such beams; therefore, no ref-
erences are currently available on the characterization of such detectors for FFF beams.
The detectors response in terms of light output as a function of the absorbed dose
is displayed in figure 3.9 for 6 and 15 MV photon beams. Standard deviations of the
measurements were below 3% (1 SD) in all cases and below 2% in more than 80% of
the measuring points. A linear function using the proportional-weighted least squares
approach was fitted to the measured data.
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Figure 3.8: Energy dependence of TLD-2000F, MCP-Ns and MTS-7s for the photon and electron
beams selected.
TLD-2000F and MCP-Ns exhibited a linear response to the absorbed dose within
the range [0.2-20] Gy, which widely covers the typical doses involved in radiotherapy
treatments. Ginjaume et al. 121 found that standard-thickness 7LiF:Mg,Cu,P (TLD-
700H) detectors exhibited a linear response (within 3%), up to a dose of 9 Gy. For higher
doses a slight sub-linearity was observed. Sub-linear dose response can be described
simply as exponential saturation of the available trapping centers in the TL material and
therefore, it depends on the concentration of dopants. On the other hand, the higher
the TL mass, the higher the light output (signal) captured by the photomultiplier of
the TLD reader—for equivalent dose exposure. For standard-thickness TLDs and high
dose exposures (above 10 Gy), the sub-linear response observed might be more likely a
consequence of the light output saturation of the reader rather than derived from the
physical properties of the TL material. Hence, the difference in mass between TLD-
2000F and TLD-700H (20µm vs. 0.7 mm might be the cause of such disagreement of
results.
On the contrary, MTS-7s showed a two-step supra-linear behavior, one at around 2-
2.5 Gy and one at around 8-9 Gy, both for 6 and 15 MV photon beams. Supra-linearity
of MT-based TLDs had been previously shown112;121. The most widely accepted model
of supra-linearity in MT TLDs is based on “competition during heating”, i.e. on the
presence of non-TL-producing competing traps and on the presence of a spatial correla-
tion between some fraction of electron traps and recombination centers136;137. The dose
prescribed to the tumor is typically delivered in 2 Gy per fraction in conventional treat-
ments. Therefore, the supra-linearity of MTS-7s might not be a constraint on its use for
treatment plan verification since detectors might be kept within their linear response
region. For hypofractionated treatments involving higher doses per fraction, the varia-
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Figure 3.9: Detectors response to dose for 6 and 15 MV photon beams and percentage difference of
experimental measurements and linear fit.
tion of the dose response at 8 Gy approximately should be born in mind. TLD-2000F,
MCP-Ns and MTS-7s are suitable for absorbed dose measurements in radiotherapy,
although the use of MTS-7s deserves a word of caution according to their supra-linear
behavior; MTS-7s must be calibrated within the appropriate linearity range.
TLD-2000F and MCP-Ns offered a higher sensitivity than MTS-7s, which is in
good agreement with other publications112;117. Due to the absence of Ti, the increased
concentration of Mg is transformed into an increased number of trapping centers, re-
sulting in a further growth of TL signal being observed. MTS is a good example of
the occurrence of only the first of these effects: an unknown reason allows competitors
to be avoided, but the presence of Ti hampers the growth of the number of trapping
centers. Nevertheless, this is not a limitation for the use of MT-based dosimeters in
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Figure 3.10: Structure of EBT Gafchromicr films used in this study.
Layer ρ (g/cm3)
Composition (weight %)
C H O N Li Cl
Active 1.10 57.4 9.4 16.4 13.2 0.8 2.9
Surface 1.20 32.3 6.5 20.5 21.6 2.3 16.8
Clear polyester 1.35 65.2 4.2 33.3 - - -
Table 3.2: Density (ρ) and atomic composition (fraction by weight (%)) of the EBT components.
radiotherapy since the typical dose values are high enough to generate significant light
outputs.
3.2.2 Radiochromic films
EBT and EBT2 Gafchromicr films (International Specialty Products, Wayne, NJ)
were considered in this study. EBT consist of two active layers, sandwiched between
polyester138. The film responds to radiation exposure by forming a blue colored poly-
mer with an absorption peak at 636 nm. It can be used with doses from 10 cGy to
10 Gy. The film is composed principally of elements with atomic number less than 10,
but contains a small amount of chlorine making the effective atomic number similar to
that of water (ZEBTeff =6.98; Z
water
eff =7.3). The structure of the film model is described
in figure 3.10. It is made by laminating two film coatings with an active layer ap-
proximately 17µm thick and a surface layer approximately 3µm thick. The coatings
are applied to clear, transparent 97µm polyester. The overall atomic composition of
EBT Gafchromicr film is H (39.7%), C (42.3%), O (16.2%), N(1.1%), Li (0.3%) and
Cl (0.3%)—as quoted by the manufacturer. The composition of each layer is listed in
table 3.2.
In 2009, International Specialty Products stopped sales of EBT film and now offers
a similar radiochromic film product under the name Gafchromicr EBT2. The active
component of EBT2 is the same as EBT. The most obvious difference between EBT2
and its predecessor is the yellow color of the film. This arises from the presence of
a dye incorporated in the active layer. The principal purpose of this dye, referred
to as a marker dye, is to establish a reference against which the response of the film
can be measured; resulting in a net response that is independent of small differences
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Figure 3.11: Structure of EBT2 Gafchromicr films used in this study.
Layer ρ (g/cm3)
Composition (weight %)
H Li C N O Cl K Br
Polyester 1.35 4.20 - 62.5 - 33.3 - - -
Adhesive 1.20 9.55 0.90 57.8 0.23 27.8 1.73 0.64 1.30
Active 1.20 4.44 - 65.6 - 24.9 - - -
Table 3.3: Density (ρ) and atomic composition (fraction by weight (%)) of the EBT2 components.
in the thickness of the active layer. Similar to EBT, EBT2 has high atomic number
components (chlorine, bromine, and potassium) that increase its Zeff. EBT2 have
ZEBT2eff =6.84. The structure of the film model is described in figure 3.11. The active
layer is 30µm-thick and has a density of 1.20 g/cm3. The atomic composition of each
layer is listed in table 3.3 according to manufacturer specifications. It must be born
in mind that the composition of these layers is a good faith estimate based on the
proportion of the chemical constituents but it should not be used as a specification, as
quoted by the manufacturer.
EBT films were scanned by means of an Epson Perfection 4990 Photo scanner (Seiko
Epson Corporation, Nagano, Japan) and EBT2 by means of an Epson Expression
10000 XL Color Flatbed scanner (Seiko Epson Corporation, Nagano, Japan) 24 hours
after irradiation on a film area guide. Films were scanned at 72 ppm resolution in
transmission mode without any correction. Images were stored as TIFF files (RGB, 48
bits). Background and the three RGB scanning channels were taken into account for
dose conversion by means of a 3-order polynomial calibration curve.
All the international recommendations for radiochromic film dosimetry were fol-
lowed43.
Films characterization was performed at the Hospital de la Santa Creu i de Sant
Pau (HSCSP) in Barcelona and at the Hospital Duran i Reynals—Institut Catala`
d’Oncologia Barcelona (ICOB). EBT139;140 and EBT2141;142 characterization have been
previously reported. Energy dependence was found to be reasonably constant (±2%)
within the range [Co60-RX 18 MV], which is in good agreement with other publica-
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Chapter 4
On the suitability of ultra-thin
detectors for the absorbed dose
determination in the presence of
high-density heterogeneities
Considering the issue brought up in section 1.4.3, in this section we investigated the
potential suitability of several detectors for the absorbed dose measurements in the
presence of high-density media. Ultra-thin thermoluminescent dosimeters (TLDs) and
radiochromic films (EBT2) were considered. The choice of these detectors lies on their
small size, which presumably brings a small electron fluence perturbation factor p (see
section 1.4.3). Monte Carlo (MC) dose calculations were used to validate and explain
the experimental results and to investigate the perturbation effects of the detectors.
4.1 Experimental setup
The detectors were utilized to measure percentage depth-dose (PDD) curves in a slab
water phantom (Plastic WaterTM (PW), Computerized Imaging Reference Systems
(CIRS), Norfolk (VA), electronic density relative to water ρwe =1.03) with a bone-
equivalent heterogeneity (cortical, CIRS, ρwe =1.78). The phantom consisted of 30 ×
30 cm2 slabs with thicknesses ranging from 0.1 to 5 cm. The studied experimental
configuration was 5 cm of PW followed by 5 cm of bone and 10 cm of PW (see figure
4.1).
PDD curves were measured for 6 and 18 MV x-ray beams from the Varian Clinac
2100 C/D linac described in section 3.1.1.2. The previously characterized MCP-Ns,
MTS-7s and TLD-2000F TLDs as well as EBT2 Gafchromicr films (see section 3.2)
were used to measure the PDDs. Up to 9 TLDs were used at each depth to reduce
statistical uncertainty. 2-10 film pieces have been used at each depth and each piece
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Figure 4.1: The experimental configuration.
has been read 3 times.
As a first approximation, perturbation factors (p) of the detectors (see section 1.4.3)
were assumed to be negligible, i.e. the detector was assumed not to be perturbing the
charged particle fluence (including its distribution in energy) existing in the medium
in the absence of the cavity.
Detectors were calibrated to yield Dw regardless of the medium they are embedded
in.
4.2 MC dose calculations
4.2.1 MC dose distributions
Monte Carlo (MC) simulations were used as the reference data for the evaluation of the
TLDs and EBT2. Simulations were done with the PENELOPE code144 and penEasy145
was used as the main program. More details regarding the code were given in section
3.1.1.3.
Cutoff energies within the phantoms were fixed at 50 and 10 keV for electrons and
photons, respectively. For the PDD curves, the spatial resolution in depth was set to
0.05 cm.
MC simulations give dose to medium (Dm). For comparison purposes, MC dose re-
sults were expressed in terms of Dw within the bone region by applying the correspond-
ing Bragg-Gray stopping power ratio water-bone (Sw,b)
33 as described in Ferna´ndez-
Varea et al. 37 .
4.2.2 MC simulation of the detectors (cavities)
Aiming to understand the experimental results and the physics behind them, the de-
tectors were simulated with MC. MTS-7s and MCP-Ns were simulated as cylindrical
cavities of 4.5 mm with a sensitive LiF layer of 50µm plus a 0.87 mm LiF substrate.
TLD-2000F were simulated as cylindrical cavities of 20µm. The polyimide tape on
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6 MV 18 MV
Sdet,med This work Others This work Others
Sw,air 1.114 1.115
37 1.088 1.08737
Sw,bone 1.138 1.138
37 1.131 1.13137
Sw,LiF 1.247 1.244
47 1.248 1.24647
Sw,EBT2 1.008 - 1.007 -
Sbone,LiF 1.042 - 1.043 -
Sbone,EBT2 0.890 - 0.890 -
Table 4.1: Stopping-power ratios calculated at a depth of 10 cm for the 6 and 18 MV beams.
which the powder is fixed (see section 3.2.1) was dismissed as a first approximation due
to its reduced thickness (approximately < 25µm). EBT2 were simulated according
to manufacturers’ specifications as displayed in figure 3.11 and the absorbed dose was
scored in the active layer.
To further investigate the origin of potential perturbation effects of detectors, two
more cavities were studied: (i) a 50µm-thick LiF cavity, to evaluate the effect of the
inert substrate of MCP-Ns and MTS-7s, and (ii) a 20µm-thick LiF sensitive volume
plus a 25µm-thick Kapton substrate as quoted by manufacturers of TLD-2000F.
In order to reduce computation times and improve the statistics of the results, the
calculations were split into 8 separate—statistically independent—simulations that ran
in parallel on 8 separate CPUs.
The dose was expressed in terms of Dw using the corresponding stopping power ra-
tios which were obtained using the methodology described by Ferna´ndez-Varea et al. 37 .
The corresponding stopping power ratios were calculated: Sw,LiF and Sw,EBT2, which
were used to convert the dose inside the water (w) region; and Sbone,LiF and Sbone,EBT2
together with Sw,bone, which were used to convert the dose inside the bone region. The
values are shown in table 4.1 and compared (when possible) to other publications. Sw,air
was included for comparison purposes.
4.2.3 MC fluence calculation
Particle energy fluences inside the detectors (cavities) were computed and compared to
the fluence in the medium (bone) in the absence of the detector in order to evaluate
the potential correction factor p33. The comparison was made for the detectors placed
at 7 cm in depth of the studied phantom (i.e. inside the bone region).
As for the simulation of the detectors, calculations were split into 8 separate—
statistically independent—simulations that ran in parallel on 8 separate CPUs.
4.2.4 Simulation parameters and variance reduction techniques
Several variance reduction techniques were used to speed up the calculations.
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(a) MC cavities (PDD)
(b) MC energy fluence
Figure 4.2: MC geometry construction for the dose (a) and fluence (b) computations inside the
cavities for TLD-2000F.
Absorption energy for electrons and photons (Ee
−,ph
abs )—defined in section 3.1.1.1—
was set to 1.5 keV inside the cavities. A preliminary study of electron ranges with
energy found this value appropriate to avoid bias in the MC calculation. As for the
rest of simulation parameters we set: C1 = C2 = 0.02, WCC = 0.1 keV and WCR = Eabs.
Outside the cavities the simulation criteria were more generous. The absorption
energies were set as Ee
−
abs = 100 keV and E
ph
abs = 7.5 keV. The other parameters were
set as follows: C1 = C2 = 0.1, WCC = 1 keV and WCR = E
ph
abs.
In order to avoid dose computation discontinuities, cavities were embedded in a
region where the simulation parameters values were identical to those inside the cavities.
Further, an outer volume was used to apply splitting and therefore, score more energy
depositions inside the region of interest. Figure 4.2 shows the geometry for the MC
scoring of the dose and fluence inside the detectors.
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4.3 Results
4.3.1 PDD curves on the heterogeneous phantom
Measured PDD curves and the discrepancies with respect to MC are displayed in figure
4.3. Relative dose measurements were obtained within 2% statistical uncertainty.
Inside the bone region, MTS-7s, MCP-Ns provided comparable results for both
beam energies and different field sizes. For this reason, only MTS-7s measurements are
included in the 18 MV plots (figure 4.3 (d)-4.3(f)). Both detectors tended to underes-
timate the absorbed dose in bone by 4-5%. EBT2 exhibited comparable accuracy to
MTS-7s and MCP-Ns. On the contrary, TLD-2000F were able to determine the dose
inside the bone-equivalent heterogeneity with reasonable accuracy—differences with re-
spect to MC were within 2% in most cases. This behavior was observed regardless of
the beam energy and field size.
4.3.2 Cavities simulation
The results from the MC simulations of the different detectors (cavities) are shown
in figure 4.4 for the 6 and 18 MV photon beams. The MC statistical uncertainties
were below 1% in all cases. Error bars both for the MC results and the experimental
measurements have been omitted in this graph for clarity.
We found excellent agreement (within statistical uncertainties) between the MC
simulations and the experimental results for both beam energies and field sizes. The
TLD-2000F measurements were in good agreement with the MC simulations of a 20µm
LiF cavity. The MC dose computations of a 50µm-thick LiF volume plus a 0.83 mm-
thick substrate matched the experimental measurements with MCP-Ns and MTS-7s.
Finally, the MC dose scoring on EBT2 was consistent with the corresponding experi-
mental data.
As for the MC investigation of the presence/absence of substrates we found that the
simulation of the cavity of 50µm (representing the MCP-Ns and MTS-7s without the
substrate) was in good agreement with that of 20µm (TLD-2000F) within statistical
uncertainties, exhibiting a tendency to underestimate the absorbed dose in bone an
extra 1%. The results regarding the cavity of 20µm-thick LiF sensitive volume plus a
25µm-thick Kapton substrate were comparable to those of the simulation of the cavity
of 50µm (MCP-Ns and MTS-7s without the substrate) and therefore were omitted
from the figures for clarity.
4.3.3 Evaluation of electron energy fluence perturbation
Photon, electron and positron fluence distributions in energy in the different cavities
were computed and compared to those in bone in the absence of the cavities. Results
are shown in figure 4.5 for 6 and 18 MV.
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Figure 4.3: PDD curves on the slab phantom with the bone-equivalent heterogeneity.
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Figure 4.4: MC simulations of the detectors and experimental measurements.
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Figure 4.5: Particle fluence distributions in energy in the different detectors simulated compared to
the particle fluences in bone in the absence of the detectors.
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Photon fluences were identical in all cases whereas some perturbations of the elec-
tron and positron fluences were observed for the different cavities. As for the simulation
of the detectors, the results are consistent with the experimental measurements: TLD-
2000F had the lowest electron fluence perturbation effect among the detectors eval-
uated in this study—small yet not negligible. MCP-Ns, MTS-7s and EBT2 brought
comparable fluence perturbation effects and therefore offered similar accuracy in the
dose assessment in bone, although EBT2 have the smallest active volume among the
detectors studied.
As for the investigation of the effect of the presence/absence of substrates, two main
statements can be made. Firstly, a slight decrease in the electron fluence (increase of
perturbation effect) can be noticed for the cavity of 50µm (representing the MCP-Ns
and MTS-7s without the substrate) compared to that of 20µm (TLD-2000F). Neverthe-
less, this slight though perceptible change in fluence becomes only a 1% underestimation
when comparing in terms of absorbed dose, according to the findings in the previous
section 4.3.3. This indicates that the presence of the ≈ 0.8 mm-thick substrate added
behind the 50µm-thick active layer of MCP-Ns and MTS-7s decreases the number of
backscattered electrons generated in bone reaching the sensitive volume, hence reduc-
ing the electron energy fluence in the cavity. Otherwise a LiF 50µm-thick cavity might
be small enough to ensure dose determination within 2% accuracy. Secondly, the re-
sults for cavity of 20µm (TLD-2000F) plus a 25µm-thick polyimide (kapton) substrate
were comparable to those for the cavity of 50µm (MCP-Ns and MTS-7s without the
substrate). This reveals that the presence of a polyimide substrate behind the sensitive
volume of TLD-2000F leads to an observable decrease of the electron energy fluence
which turns into a 1% difference in terms of absorbed dose, as for a cavity 2.5 times
larger (from 20µm to 50µm).
We have found that a LiF cavity of 50µm might be small enough to ensure dose
assessment in bone within 2% accuracy. To further develop the discussion of results,
we evaluated the influence of the material of the cavity on the results. To this aim,
we computed the fluences in a 50µm-thick cavity made of (i) water and (ii) EBT
active layer material (film), and compared them to that made of LiF. Energy fluences
are depicted in figure 4.6. No significant differences were found among the different
materials. Hence, the material composition of the sensitive volume (LiF, water or
EBT’s active layer film) does not alter the particle fluence (neither its distribution in
energy) perturbation in bone.
4.4 Conclusions
The suitability of several detectors to accurately determine the absorbed dose in bone
was evaluated. Ultra-thin TLDs and Gafchromic EBT2 radiochromic films were con-
sidered assuming that their reduced size might bring negligible/low perturbation effects
72 4.4. CONCLUSIONS
101 102 103
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
x 10−13
E (keV)
 
 
bone
MCP/MTS − substrate (50µ LiF)
MCP/MTS − substrate (50µ water)
MCP/MTS − substrate (50µ film)
EBT2
(a) 6 MV photons
101 102 103
0
1
2
3
4
5
6
7
x 10−13
E (keV)
 
 
bone
MCP/MTS − substrate (50µ LiF)
MCP/MTS − substrate (50µ water)
MCP/MTS − substrate (50µ film)
EBT2
(b) 18 MV photons
101 102 103
0
0.2
0.4
0.6
0.8
1
1.2
x 10−15
E (keV)
 
 
bone
MCP/MTS − substrate (50µ LiF)
MCP/MTS − substrate (50µ water)
MCP/MTS − substrate (50µ film)
EBT2
(c) 6 MV electrons
101 102 103
0
1
2
3
4
5
6
7
8
x 10−15
E (keV)
 
 
bone
MCP/MTS − substrate (50µ LiF)
MCP/MTS − substrate (50µ water)
MCP/MTS − substrate (50µ film)
EBT2
(d) 18 MV electrons
101 102 103
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
x 10−17
E (keV)
 
 
bone
MCP/MTS − substrate (50µ LiF)
MCP/MTS − substrate (50µ water)
MCP/MTS − substrate (50µ film)
EBT2
(e) 6 MV positrons
101 102 103
0
0.5
1
1.5
2
2.5
3
x 10−16
E (keV)
 
 
bone
MCP/MTS − substrate (50µ LiF)
MCP/MTS − substrate (50µ water)
MCP/MTS − substrate (50µ film)
EBT2
(f) 18 MV positrons
Figure 4.6: Particle fluence distributions in energy for a 50µm cavity made of different materials
compared to those in bone in the absence of the cavity and in EBT2.
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in the medium.
Experimental measurements have been carried out in a water phantom with a bone-
equivalent heterogeneity. MC simulations have been done to better understand the
experimental results.
The results revealed that all detectors that were considered for this study bring a
certain perturbation of the electron fluence and its distribution in energy inside bone.
This perturbation leads to a systematic underestimation of the absorbed dose in bone,
which arises from the difference between the effective atomic number of the detectors
(≈ 7 in all cases) and the bone-equivalent material (≈ 11). TLD-2000F (cylindrical
20µm-thick cavities) exhibited the lowest perturbation effects, providing reasonably
accurate results in bone with only 2% underestimation of the dose. MCP-Ns and MTS-
7s underestimated the dose within the bone region by 4-5%; despite the sensitive volume
of the detectors might be small enough to avoid significant perturbation (cylindrical
cavities with a thickness of 50µm), the presence of the substrate added below the TL
material is responsible for an extra 2-3% of dose underestimation due to a diminishing of
backscattered electrons from bone reaching the active volume. Further, EBT2 provided
comparable accuracy to MCP-Ns and MTS-7s in bone; the upper and lower polyester
layers embedding the active material add a non-negligible perturbation of the fluence in
bone in the absence of the detectors. Hence, TLD-2000F were found to be the detector
of choice for absorbed dose measurements in bone yet a 2% dose underestimation should
be born in mind.
The MC simulations show that a 50µm-thick detector might be small enough to
provide the dose assessment in bone within a 2% accuracy, regardless of the tested
material composition—LiF, water or EBT’s active layer film.
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Chapter 5
On the dosimetric validation of
Acuros XB in heterogeneities
In November 2010, Varian Medical Systems received clearance form the US Food and
Drug Administration to market their new dose calculation algorithm, Acurosr XB
(AXB). Based on the general-purpose radiation transport modeling system, Attilar,
first developed at Los Alamos National Laboratory in Los Alamos, New Mexico, AXB
has been modified and optimized for radiation therapy planning calculations.
The AXB advanced dose calculation algorithm has been developed to address two
strategic needs of external photon beam treatment planning: accuracy and speed. This
algorithm implemented in the EclipseTM treatment planning system (TPS) uses a so-
phisticated technique to deterministically solve the linear Boltzmann transport equation
(LBTE) (see equation 1.2 and 1.1 in chapter 1) using an iterative approach.
AXB directly accounts for the effects of heterogeneities in patient dose calculations.
Hence, the algorithm can provide comparable accuracy to Monte Carlo simulations
(MC). The impetus behind the development of explicit LBTE solution methods is to
provide a rapid alternative to MC simulations, which are known to be time-consuming.
With sufficient refinement, both MC and AXB are expected to converge to the same
dose predictions146. The achievable accuracy of both methods is potentially equivalent
and only constrained by the available computational resources. For practical reasons,
a limited number of histories are possible for a MC simulation, and a limited finite
sampling of the energy groups, beam angles and beam geometries is possible for AXB.
Based on other publications, AXB achieved a comparable computation time with the
clinically used Collapsed-Cone Convolution (CCC) algorithm147;148.
The main features of the algorithm are described below. Further details on the
algorithm can be found elsewhere146.
This study was developed in collaboration with the Hospital Josep Trueta, Institut
Catala` d’Oncologia Girona (ICOG), Girona, Spain.
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5.1 AXB background
The Boltzman transport equation describes the macroscopic behavior of radiation as
it travels through and interacts with matter. The LBTE assumes that particles only
interact with the matter they are passing through and not with each other. This
assumption is valid for conditions without external magnetic fields. In this case, the
solution to the LBTE would give an “exact” description of the absorbed dose within a
given volume. Since analytic solutions (closed forms solutions) to the LBTE can only
be obtained for a few simplified problems, the LBTE must be solved in an open form
or non-analytic manner.
There are two general approaches to obtaining open form solutions to the LBTE.
The first approach is the widely known MC method, which do not explicitly solve the
LBTE but obtains the solution indirectly. The second approach is to explicitly solve it
using “convergent” numerical methods, like AXB does. In the explicit LBTE solution
methods, errors are primarily systematic and result from discretization of the variables
in space, angle, and energy. Larger steps in the discretization process result in a faster
solution, but less accuracy.
5.1.1 Source model in AXB
AXB source model consists of four components149:
• Primary source: it is a user-defined circular or elliptical source located at the
target plane which models the bremsstrahlung photons created in the target that
do not interact in the treatment head.
• Extra-focal source: it consists of a Gaussian plane source located at the bottom
of the flattening filter, which models the photons that result from interactions in
the accelerator head outside the target (primary in the flattening filter, primary
collimators, and secondary jaws).
• Electron contamination: it represents the dose deposited in the build-up region,
not accounted for by the primary and extra-focal source components.
• Photons scattered from wedge: it represents the scatter from hard wedges. It is
implemented with a dual Gaussian model, where the width of the Gaussian kernel
increases with distance from the wedge.
5.1.2 Dose calculation
The AXB patients’ transport consists of four discrete steps, which are performed in the
following order:
1. Transport of source model fluence into the patient.
CHAPTER 5. ON THE DOSIMETRIC VALIDATION OF ACUROS XB IN
HETEROGENEITIES 77
2. Calculation of scattered photon fluence in the patient.
3. Calculation of scattered electron fluence in the patient.
4. Dose calculation.
In Step 1, the machine sources are modeled as external sources and ray tracing is
performed to calculate the uncollided photon and electron fluence distributions in the
patient. In Step 2 and 3, AXB discretizes in space, angle, and energy, and iteratively
solves the LBTE. In Step 4, the dose in any voxel is obtained by applying an energy-
dependent fluence-to-dose response function to the local energy-dependent electron
fluence in that voxel. When dose-to-medium (Dm) is calculated, the energy-dependent
response function is based on the material properties of that voxel. On the contrary,
when dose-to-water (Dw) is calculated, the energy-dependent fluence-to-dose response
function is based on water.
Unlike convolution/superposition algorithms, where heterogeneities are generally
handled as density-based corrections applied to dose kernels calculated in water, AXB
explicitly models the physical interactions of radiation with matter. To do this, AXB
requires the chemical composition of each material in which particles are transported
through, not only the density. EclipseTM provides AXB with a mass density and
material type in each voxel of the image grid—computed tomography (CT). Its material
library includes five biological materials (lung, adipose tissue, muscle, cartilage, and
bone) and 16 non-biologic materials. The material composition is specified in tables
5.1 and 5.2.
5.1.3 Material specification
Material determination is done in two ways for AXB. The default method used to
determine the material composition of a given voxel in a 3D image is based on the
Hounsfield Unit (HU) value. The HU value in the voxel in converted to mass density
using the CT calibration curve. The curve can be configured by the users for their
specific CT scanner. Once mass density is known in a voxel, the material is determined
based on a hard coded look-up table stored in the Varian system database. This
automatic conversion is used for all voxels with mass density below 3 g/cm3. Any voxel
with density higher than 3 g/cm3 requires user assignment. Furthermore, the automatic
material assignment only assigns biological materials to voxels. Based on their mass
density, voxels will be assigned lung, adipose tissue, muscle, cartilage, or bone.
Any noise present in the CT image is transformed directly into a noise in the mass-
density map of the image. In the regions of the CT image where the mass density is
very close to a minimum/maximum value of two materials. The discrete nature of the
material assignment and the noise in the CT image may lead to a rapid alternation
between two different material assignments. Depending on the strength of the noise
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Material Zeff Element Weight Fraction
Lung (ICRP 1974) 8.14
H 0.101278
C 0.102310
N 0.028650
O 0.757072
Na 0.001840
Mg 0.000730
P 0.000800
S 0.002250
Cl 0.002660
K 0.001940
Ca 0.000090
Fe 0.000370
Zn 0.000010
Adipose tissue (ICRP 1975) 5.91
H 0.119477
C 0.637240
N 0.007970
O 0.232333
Na 0.000500
Mg 0.000020
P 0.000160
S 0.000730
Cl 0.001190
K 0.000320
Ca 0.000020
Fe 0.000020
Zn 0.000020
Muscle, Skeletal (ICRP 1975) 7.13
H 0.100637
C 0.107830
N 0.027680
O 0.754773
Na 0.000750
Mg 0.000190
P 0.001800
S 0.002410
Cl 0.000790
K 0.003020
Ca 0.000030
Fe 0.000040
Zn 0.000050
Table 5.1: Material composition in AXB (v.10.0.28). From Failla et al. 146 .
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Material Zeff Element Weight Fraction
Cartilage (ICRP 1975) 7.38
H 0.096
C 0.099
N 0.022
O 0.744
Na 0.005
Mg NA
P 0.022
S 0.009
Cl 0.003
K NA
Ca NA
Bone (ICRP 1975) 8.14
H 0.047234
C 0.14433
N 0.04199
O 0.446096
Mg 0.0022
P 0.10497
S 0.00315
Ca 0.20993
Zn 0.0001
Aluminum 13 Al 1
Table 5.2: Material composition in AXB (v.10.0.28). From Failla et al. 146 .
and on the calculation grid size this effect may be seen in these regions as a slight noise
in the dose distribution146.
The list of supported materials with associated density ranges is provided in table
5.3.
Material
Density (g/cm3)
Low Nominal High
Lung (ICRP 1975) 0.000 0.260 0.590
Adipose tissue (ICRP 1975) 0.590 0.920 0.985
Muscle, skeletal (ICRP 1975) 0.985 1.050 1.075
Cartilage (ICRP 1975) 1.075 1.100 1.475
Bone (ICRP 1975) 1.475 1.850 3.000
Table 5.3: Material mass densities in AXB (v.10.0.28) (automatic CT-to-material conversion). From
Failla et al. 146 .
5.1.4 Dw and Dm in AXB
Both AXB and MC methods calculate Dm based on energy deposition. However,
when calculating Dw in non-water materials, AXB and MC methods employ different
approaches.
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MC methods will generally calculate Dm and employ stopping power ratios to con-
vert Dm into Dw, as it has been previously mentioned in this manuscript.
On the contrary, AXB calculates the energy-dependent electron fluence using the
material composition of the patient, regardless of whether Dw or Dm is selected, as
stated above. When Dw is selected, in non-water materials this is analogous to calcu-
lation the dose received by a volume of water which is small enough to not significantly
perturb the energy-dependent electron fluence. Due to the very short range of low-
energy electrons, this volume may be much smaller than either the dose grid voxel size
or detectors used to experimentally measure Dw. This effect is most significant for
bone and non-biologic, high-density materials such as aluminum, titanium and steel.
Hence, whereas MC methods use collisional stopping power ratios to determine the
ratio Dw/Dm, it is reflected in the energy-deposition ratios in AXB.
5.1.5 On the AXB validation
Vassiliev et al. 21 validated in 2010 a pre-clinical version of the algorithm against Monte
Carlo (MC) (EGSnrc)150 in an extensive variety of materials and reported excellent
agreement between both dose calculation methods. They used an heterogeneous slab
phantom whose configuration was: water-bone-lung-water. Depth-dose distributions
were evaluated for different field sizes. Maximum relative differences between AXB
and MC were encountered in the lung region. These were found to be less than 1.5%
and 2.3% (local dose differences) for 6 and 18 MV, respectively. Encouraging results
were also found for an anthropomorphic phantom.
Since then, several studies have been published on the evaluation of the released
AXB in water and heterogeneous phantoms. Most of these studies also included su-
perposition/convolution algorithms as the current standard, such as AAA or the CCC
method. AXB has been compared in simple geometries using virtual phantoms for
single photon beams either against MC simulations147;151–153 or against experimental
measurements154. In general, the dose accuracy yielded by AXB has been reported
to be comparable to that of MC simulations and AXB has been presented as a sig-
nificant improvement over the current algorithms in the presence of high-density and
low-density media. Few studies have validated the algorithm experimentally for more
complex treatments, such as IMRT or VMAT148;155–158.
Han et al.148;156 used films and TLD measurements to verify IMRT and VMAT
plans mainly in water-equivalent regions and Kan, Leung, and Yu 157 validated ex-
perimentally the dose at/near the heterogeneity interfaces. Hence, the effects from
heterogeneities could not be fully investigated. Only Kan et al. 158 reported, in a recent
publication, film measurements within the heterogeneous medium of the nasopharygeal
region of an anthropomorphic phantom. Thus, experimental measurements inside the
heterogeneities have not been reported yet. The validation of a treatment planning sys-
tem requires the comparison against both experimental measurements and MC results.
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Both MC and AXB dose calculations might be affected by similar sources of uncer-
tainty, such as those arising from the radiation source modeling or from the materials
definition (atomic composition, mean excitation energy). In this sense, experimental
measurements might be essential to procure real dose estimations provided a proper
detector is available.
These studies also investigated both dose-reporting methods available in AXB,
i.e. Dw and Dm, but did not include the MC for a fair comparison in terms of Dm—
detectors are calibrated to yield Dw and they are placed in water-equivalent regions.
Apart from these, only the work of Han et al. 147 compared Dw and Dm in AXB against
MC, but quantitative comparisons where reported only in terms of Dm and the study
did not include measurements. For the mentioned reasons, there is still room for further
investigation of the behavior of AXB in heterogeneities.
In this study, we examined the accuracy of the AXB dose calculation algorithm
in phantoms with lung-equivalent and bone-equivalent heterogeneities using both MC
simulations and experimental measurements for different photon beam energies and
field sizes. AAA was also included in the comparison. The two dose-reporting methods
in AXB (Dw and Dm) were analyzed and the potential influence of the use of virtual
phantoms or CT images on the dose calculations was also evaluated. All AXB and
AAA dose calculations were performed by the radiophysicists at ICOG.
5.2 Experimental setup for the AXB verification
Two photon beam energies, 6 and 18 MV, from a Varian Clinac 2100 C/D (Varian,
Palo Alto, CA) linear accelerator and four field sizes ranging from 2× 2 to 20× 20 cm2
were considered.
Percentage depth-dose (PDD) curves and dose profiles normalized to central axis
were evaluated on a water-equivalent slab phantom (PTW RW3, electron density rela-
tive to water ρwe =1.012) with (i) a lung-equivalent heterogeneity (Computerized Imag-
ing Reference Systems (CIRS), Norfolk (VA), ρwe =0.195) and (ii) a bone-equivalent
heterogeneity (cortical bone CIRS, ρwe =1.779). The phantom consisted of 30× 30 cm2
slabs with thicknesses ranging from 0.1 to 5 cm. PDDs and lateral profiles were nor-
malized to the maximum dose.
The studied experimental configurations were (i) 5 cm of RW3 followed by 13 cm of
lung and then by 10 cm of RW3, and (ii) 5 cm of RW3 followed by 5 cm of bone and
10 cm of RW3 (see figure 5.1). Although the second configuration was unrealistic from
a clinical perspective—therapy fields would rarely traverse such thickness of cortical
bone—it provided a wider region to evaluate the behavior of the algorithm.
Dose profiles were evaluated (i) in the slab phantom with the lung-equivalent het-
erogeneity at a depth of 10 cm, and (ii) in the slab phantom with the bone-equivalent
heterogeneity at a depth of 7 cm; both were compared against their corresponding dose
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(a) (b)
Figure 5.1: The experimental configurations.
profiles in water to quantify the change in beam penumbrae.
Virtual phantoms were generated for AXB, AAA and MC calculations. The mate-
rial in each region of the phantom (water, lung or bone) was selected from the materials
available in EclipseTM (see tables 5.1-5.3) and the electron density was set equal to
the nominal value specified by manufacturers by adjusting the CT number. One should
bear in mind that, as stated above, the materials available in AXB are biological ma-
terials whereas the experimental setup consists of plastic materials—and therefore the
elemental composition might differ. This may be a source of discrepancy in the dose
comparisons to experimental measurements, and it must be taken into account when
discussing the results. As a first step, we computed the dose distributions on the
heterogeneous phantoms using the materials in AXB (ICRP) and the plastic materials
(CIRS) available at our facility for the heterogeneous regions. The comparison is shown
in figure 5.2 for one of the beam configurations both in terms of Dm and Dw for lung
and bone. When comparing in terms of Dw, we found excellent agreement between
both types of bone whereas differences of about 2% were observed in lung.
Dose distributions were also obtained using the CT images of the phantoms to
evaluate the effects of artifacts arisen from the image acquisition and the material
assignment procedure on the final dose computations. Identical HU-to-mass density and
HU-to-material conversion curves (see figure 5.3) were used in AXB and MC to avoid
a potential source of discrepancy on material assignment. This offers a fair comparison
between both calculation methods. The experimental measurements are essential in
this approach, allowing the evaluation of the potential effect of the automatic material
assignment procedure on dose distributions. Images were generated on an Optima
CT580RT CT scanner (General Electric Healthcare, Fairfield, CT). The field-of-view
was set to 65 cm and the voxel size was fixed to 1.27× 1.27× 5 mm3.
The three source model used in AXB (v.10.0.28) and AAA (v.10.0.28) was auto-
matically configured using the default focal spot size of 1 mm in x and y directions159.
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Figure 5.2: MC dose distributions on the heterogeneous phantoms for 18 MV and a 5× 5 cm2 field
comparing the biological materials (ICRP) against the plastic materials (CIRS) in terms of Dm and
Dw.
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Figure 5.3: HU-to-density calibration curve integrated in the TPS. The density-to-material conversion
is also specified.
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The output calculation grid was set to 0.2× 0.2× 0.2 mm3.
Comparisons were made in terms of Dw since detectors were calibrated to yield
Dw. A comparison between AXB and MC in terms of Dm was also performed for the
phantom with the bone equivalent heterogeneity.
AXB, AAA and MC were initially validated in water for 6 and 18 MV photon beams
against experimental measurements. Output factors, PDD and dose profiles for open
and enhanced dynamic wedge (EDW) fields (ranging from 2 × 2 to 40 × 40 cm2) were
measured in water using PTW semiflex ionization chamber (IC) (Freiburg, Germany),
PTW Roos IC, Scanditronix PFD-3G diode and PTW-LA48 linear array detectors,
respectively.
5.2.1 Photon MC dose calculations
Simulations were done with the PENELOPE code144 and penEasy145 was used as the
main program (see chapter 3 for more details).
As the authors have reported elsewhere63, simulations were done in two steps, as
stated in section 3.1.1.4 of this manuscript. Phase-space files stored about 3 · 108
particles to ensure the statistical uncertainty to be below 2% for dose distributions.
Cutoff energies within the phantoms were fixed at 50 and 10 keV for electrons and
photons, respectively. For the PDD curves, the spatial resolution in depth was set to
0.1 cm, although it was reduced to 0.05 cm at the interfaces to accurately account for
the steep dose gradient when switching from one medium to another, especially in bone.
Dose profiles were obtained with a spatial resolution of 0.1 cm at a particular depth.
MC simulations give Dm. For comparison purposes, MC dose results were expressed
in terms of Dw when required by applying the corresponding Bragg-Gray stopping
power ratio water-medium (Sw,med) as described in Ferna´ndez-Varea et al.
37 .
5.2.2 Experimental measurements
All detectors were calibrated to yield Dw regardless of the media they were embedded
in.
5.2.2.1 Ionization chambers
Two types of IC were used to measure PDD curves: 0.35 cm3 Roos (PTW, Freiburg,
Germany) and 0.016 cm3 PinPoint 31016 (PTW, Freiburg, Germany). Both were con-
nected to the UNIDOS electrometer (PTW, Freiburg, Germany). Due to their physical
dimensions, the Roos IC was used for the largest fields (10× 10 cm2 and 20× 20 cm2),
whereas the PinPoint 31016 IC was preferred for the smallest fields measurements
(2× 2 cm2 and 5× 5 cm2). IC measurements were carried out by the radiophysicists at
ICOG.
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Dosimetry protocols provide a set of correction factors for converting ionization
into dose, but only for water-equivalent materials and at a reference depth40;41 (as
detailed in section 1.4.3). The AAPM Report No. 8520 clearly states that ionization
measurements from parallel ionization chambers cannot be used inside tissues other
than water without applying a correction factor from the fluence perturbation caused
by the presence of the chamber in the medium. Since such factors are unknown for
our IC, only TLDs were used in lung and bone in this study. In particular, ultra-thin
dosimeters (< 0.01 cm-thick) were chosen to avoid perturbation effects in bone.
5.2.2.2 Thermoluminescent dosimeters
Two types of TLD were used: 7LiF:Mg,Ti (TLD-700, Thermo Fisher Scientific Inc.,
Erlangen, Germany) and LiF:Cu,Mg,P (TLD-2000F, Conqueror Electronics Technology
Co. Ltd., Beijing, China). The main features of TLD-2000F are described in section
3.2.1.
The thermoluminescent materials chosen have an effective atomic number similar
to soft tissue, which minimizes potential perturbation effects when measuring in soft
tissue or water. However, especial care must be given in the case of bone. Whereas
lung is quite similar to water or soft tissue in terms of effective atomic number, bone
differs significantly. According to the finding presented in section 4.3, TLD-2000F were
the detectors of choice inside the bone-equivalent region. For the dose measurements in
lung we used TLD-700, which have been previously shown to be suitable for this kind
of measurements63.
Standard annealing and readout were carried out as described in section 3.2.1.
Several detectors (up to 9, depending on the field size) were used at each depth in
order to reduce the statistical uncertainty of the results. Likewise, some measurements
were repeated up to three times. This, together with the application of individual
correction factors and a sensitivity stability control, allowed to achieve results with
statistical uncertainties of ±1-2% in all cases.
5.2.2.3 Films
Film dosimetry was preferred for measuring lateral profiles to avoid the influence of
the finite detector size and to improve the spatial resolution. Gafchromic R©EBT ra-
diochromic films (International Specialty Products, Wayne, NJ) from a single batch
together with an Epson Perfection 4990 Photo scanner (Seiko Epson Corporation,
Nagano, Japan) were used. Film measurements were carried out by the radiophysi-
cists at ICOG. Main detectors’ features as well as readout procedures are described in
section 3.2.2.
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5.3 Results
5.3.1 AXB validations in water
AXB validation in water was carried out at ICOG. Output factors for open and EDW
fields were within 1% and 1.3%, respectively, compared to experimental measurements.
Small systematic differences might be attributable to the beam source modeling. The
average deviations for PDD were 0.4% in dose, and distance-to-agreement (DTA) was
below 2 mm for all cases, except for the build-up region of the 18 MV 40 × 40 cm2
open field. For the profiles, deviations were within 1% for 6 MV and 2% for 18 MV in
the inner field region (80% nominal field size). DTA was below 1 mm in the penumbra
region—defined as the distance between the 80% and the 20% of the central axis dose—
for all cases, including EDW fields. These results were in good agreement with the study
of Fogliata et al. 151 .
The validation of the MC PDD curves and lateral profiles for 6 and 18 MV photon
beams in water were presented in chapter 3 in figures 3.1-3.4.
5.3.2 AXB validations in the heterogeneous phantoms
5.3.2.1 Central-axis doses
Figures 5.4-5.6 show the measured and calculated PDD curves for the selected photon
energies and field sizes for the two heterogeneous phantoms. Differences relative to MC
are also displayed in the figures. AXB vs. MC dose comparisons in terms of Dm are
also included for the phantom with the bone-equivalent heterogeneity (figure 5.6).
MC results were yielded within 1% statistical uncertainty (2 standard deviations
(SD)). IC and TLD measurements were obtained with statistical uncertainties below
1% and 2%, respectively. The agreement with MC was within 2% in 98% of the cases.
Exceptionally, differences up to 3% were found at the lung heterogeneity interfaces and
up to 4% within the lung region for the 2 × 2 cm2 field size of both 6 and 18 MV
photon beams. Such remaining slight differences might be attributable to the fact that
MC calculations are computing the dose on biological materials, whereas experimental
measurements are carried out on plastics.
The agreement of AXB and AAA with MC in terms of Dw was evaluated using
gamma index analysis with an acceptability criterion 2% dose difference and 2 mm
DTA. The passing rate is presented in table 5.4 for all the studied configurations.
5.3.2.1.1 Lung. AXB dose distributions along the phantom with lung-equivalent
material were in excellent agreement with MC (within 2%) beyond the depth of max-
imum dose in most cases (see figures 5.4 and 5.5). Maximum differences of 4% were
found within the first 1 to 3 cm after the interface water/lung for the 2×2 cm2 field size
of both 6 and 18 MV photon beams. In this case, the passing rate was 96.1% and 92.5%
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AXB AAA
lung bone bone (Dm) lung bone
Field size (cm2) 6 MV 18 MV 6 MV 18 MV 6 MV 18 MV 6 MV 18 MV 6 MV 18 MV
2x2 96.6 92.5 - - - - 88.9 54.1 - -
5x5 99.7 99.8 74.3 75.5 97.3 99.1 82.4 75.8 72.4 71.5
10x10 99.7 99.8 79.9 75.6 99.1 99.5 66.1 71.3 77.1 70.6
20x20 99.5 99.6 87.9 78.0 99.1 97.8 29.6 96.9 68.7 66.8
Table 5.4: Percentage of points with a gamma index above 1 with a dose/distance criterion of
2%/2 mm.
for the 6 MV and 18 MV, respectively. Otherwise, the percentage of points passing the
criterion was above 99%. These results are consistent with other publications147.
AAA provided reasonable accuracy within the lung region except for the smallest
field of both photon beam energies, where discrepancies to MC were found to be up to
5.7% and 20.3% for 6 and 18 MV, respectively. The passing rate of AAA central-axis
dose distributions was below 80% in most cases, but it increased to 90% when the
criteria was raised to 3%-3 mm. In water, AAA systematically overestimated the dose
after the lung region by up to 5%.
5.3.2.1.2 Bone. In the phantom with the bone-equivalent heterogeneity we found
excellent agreement between AXB and MC when reporting the dose in terms of Dm
(see figure 5.6); the passing rate was above 99% in most cases, which is consistent
with other publications147. However, larger discrepancies—up to 4.5% for the 18 MV
photon beam—were found within the bone region when using Dw. The origin of such
differences might reside in the conversion procedure. The methods used by AXB and
MC to convert the results intoDw are distinct: whereas AXB uses an in-flight method to
give the Dw by multiplying the energy-dependent fluence by the dose-response function
of water in the output grid voxel, the MC dose distributions are converted once the
simulation has finished by using the corresponding Sw,med. The Sw,bone used in this
study were 1.117 and 1.111 for 6 and 18 MV photon beams, respectively37. However,
in AXB the jump from Dm to Dw in this region was about 15%. Differences between
AXB and MC in terms of Dw in bone of density ρ = 1.5 g/cm
3 have been found to
be slightly smaller (around 3% at most) by other authors153. The density of the bone
used herein was 22% higher, which could be the reason of such disparity of results.
Nevertheless, further investigation on this issue needs to be undertaken.
In water, both before and after the bone heterogeneity, AAA provided reasonable
accuracy. However, differences in bone were up to 5.9% and 9.6% for 6 and 18 MV,
respectively. In this region and for the 18 MV photon beam, AAA was in good agree-
ment with the AXB and MC results expressed in terms of Dm (discrepancies below
2.5%). This results are in good agreement with other studies61;147;148.
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Figure 5.4: PDD curves for the phantom with the lung-equivalent heterogeneity for 6 MV and
different field sizes.
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Figure 5.5: PDD curves for the phantom with the lung-equivalent heterogeneity 18 MV and different
field sizes.
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Figure 5.6: PDD curves for the phantom with the bone-equivalent heterogeneity for 6 and 18 MV
and different field sizes.
CHAPTER 5. ON THE DOSIMETRIC VALIDATION OF ACUROS XB IN
HETEROGENEITIES 91
Lung
E (MV) Field size EBT MC AXB AAA EBTw MCw
6
2× 2 cm2 7.6 6.6 5.9 6.9 3.6 3.4
10× 10 cm2 12.6 11.9 11.5 11.4 5.5 5.1
18
2× 2 cm2 10.7 9.7 9.9 6.6 4.9 5.1
10× 10 cm2 20.9 19.8 20.7 11.6 7.1 6.8
Bone
E (MV) Field size EBT MC AXB AAA EBTw MCw
6
2× 2 cm2 3.1 2.9 3.4 3.8 3.6 3.4
10× 10 cm2 4.3 4.5 4.5 4.7 5.5 5.1
18
2× 2 cm2 3.9 4.1 4.3 4.6 4.9 4.8
10× 10 cm2 5.2 5.0 5.2 5.3 7.1 6.6
Table 5.5: Beam penumbrae (mm) for 6 and 18 MV photon beams and two different field sizes:
2× 2 cm2 and 10× 10 cm2. Measured (EBT) and calculated (MC) beam penumbrae in water (w) are
also shown.
5.3.2.2 Lateral profiles
Measured and calculated dose profiles are shown in figure 5.7 for two field sizes: 2×2 cm2
and 10× 10 cm2 . Beam penumbrae are specified in table 5.5 for the two phantoms.
EBT films yielded the relative dose within 2% statistical uncertainty. The statistical
uncertainty associated to MC was 2% (2 SD). The agreement was within 3% in all cases.
Discrepancies in beam penumbrae were below 1.1 mm and 0.2 mm in lung and in bone,
respectively.
5.3.2.2.1 Lung. AXB and MC dose profiles were in good agreement (see figure
5.7 (a) and (b)). Differences in beam penumbrae were below 1.7 mm in all cases.
For the 6 MV photon beam, AAA dose profiles were in good agreement with those
calculated by MC—differences in beam penumbra were below 1.7 mm in all cases. How-
ever, AAA was unable to correctly predict the penumbra widening effect in lung for
18 MV photon beam regardless of the field size and discrepancies in beam penumbra
exceeded 9 mm for the 10× 10 cm2 field size compared to MC.
5.3.2.2.2 Bone. AXB and MC dose profiles were in good agreement for all beam
configurations. Differences in beam penumbrae were within 0.4 mm in all cases.
Dose profiles were correctly predicted by AAA. Maximum differences in beam
penumbrae were 0.7 mm with respect to MC.
5.3.3 On the material assignment in AXB
AXB, AAA and MC PDD curves were calculated on the CT images of the phantoms
and compared to those corresponding to the virtual phantoms. Percentage differences
are displayed in figures 5.8 and 5.9 for the lung and bone configurations, respectively.
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Figure 5.7: Dose profiles for two different field sizes (2× 2 cm2 and 10× 10 cm2) in lung (figures (a)
and (b)) and bone (figures (c) and (d)). Measured (EBT) and calculated (MC) dose profiles in RW3
are included in this plot to evaluate the spectral change of the curve.
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In general, differences were found to be below 2% beyond the dose maximum ex-
cept for the 18 MV photon beam in the phantom with the lung heterogeneity, where
discrepancies of 4% were registered both for AXB and MC within the first centimeters
of lung and in water after the heterogeneity. On the contrary, no significant differences
where found in any case for the phantom with the bone-equivalent material. AAA
yielded identical dose distributions both on the generated virtual phantoms or on the
CTs (discrepancies below 2% in all cases).
To further investigate the origin of these differences, depth-dose curves were com-
pared in terms of absolute doses for the beam energies and field sizes selected. The
comparison for the 18 MV and the 5 × 5 cm2 field size is shown in figure 5.10 for the
two heterogeneous phantoms. From figure 5.10 (a) it can be stated that the differences
observed on the right column (top and bottom) in figure 5.8 on the water region after
the heterogeneity arose from the normalization procedure. Differences of about 4%
were actually observed in the first centimeters of the phantom with the lung-equivalent
heterogeneity. The cause of this change in dose when using the CT instead of the
virtual phantom is a combination of factors that can be understood from figure 5.11.
First, water is not among the materials that AXB can assign automatically; therefore,
AXB (and MC in this case) will assign muscle to those voxels with HU around 0 (see
figure 5.3), whose effective atomic number (Zeff) is very close to that of water. However,
the HU of the voxels adjacent to the first heterogeneity interface slightly decrease due
to the presence of lung as an artifact of the CT scanner, as shown in figure 5.12. As
a consequence, the material assigned to that region appears to be adipose tissue (see
figure 5.11 (a))—whose Zeff is around 0.9 times that of water. For this reason, the
absorbed dose was lower than that reported when calculating on the virtual phantom
within the first centimeters of the phantom. This was not the case for the phantom
with the bone-equivalent heterogeneity. Whereas HU fluctuations are also observed in
the water regions adjacent to the interfaces, in this case the HU are increased owing to
the presence of bone in such a way that the material assigned is cartilage (see figure
5.11 (b)). Zeff of cartilage is again very close to that of water and the dose distribu-
tions on the virtual phantom and on the CT are in good agreement. To confirm these
findings we computed with MC the dose distributions on the virtual phantom with
the lung-equivalent material replacing the first 5 cm of water for 5 cm of (i) adipose
tissue, (ii) muscle and (iii) cartilage. Results are depicted in figure 5.13 in terms of
Dw together with the differences with respect to water computed as Dtissue/Dwater. As
expected, the dose around the depth of dose maximum is about 4% lower for adipose
than for water. On the contrary, slight differences (1-2%) are observed for muscle and
cartilage.
For the sake of completeness, the 18 MV PDD curves on the phantom configuration
with lung for the 2× 2 cm2 and 10× 10 cm2 in absolute doses are shown in figure 5.14.
Around the dose maximum, both IC and TLD measurements were in good agree-
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Figure 5.8: Differences between the calculation on the virtual phantom and on the CT for the lung
configuration for 6 MV (left column) and 18 MV (right column).
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Figure 5.9: Differences between the calculation on the virtual phantom and on the CT for the bone
configuration for 6 MV (left column) and 18 MV (right column).
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Figure 5.10: Central-axis curves on both phantoms in absolute doses for the 18 MV photon beam
and the 5×5 cm2 field size. AXB, MC and AAA calculations on the virtual phantom (continuous lines)
and on the CT images (discontinuous lines). Experimental measurements are also depicted.
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Figure 5.11: CT slices of both phantom configurations showing the material assigned to each voxel
and the density along the central axis of the phantom based on the conversion in figure 5.3.
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Figure 5.12: CT slices of both phantom configurations showing the material assigned to each voxel
and the HU-values along the central axis of the phantom based on the conversion in figure 5.3.
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Figure 5.14: Absolute central-axis curves in the phantom with lung for the 18 MV photon beam.
AXB, MC and AAA calculations on the virtual phantom (continuous lines) and on the CT images
(discontinuous lines). Experimental measurements are also depicted.
ment with the AXB and MC doses calculated using virtual phantoms. This should be
taken into account when performing experimental validations of this version of the al-
gorithm. From these findings, discrepancies of a few percent might derive from the ma-
terial assignment procedure rather than being dosimetric limitations of the algorithm.
In those regions where the mass density (or HU-value) is very close to a minimum/max-
imum value of two different materials, the discrete nature of the material assignment
procedure and slight fluctuations of HU caused by CT artifacts may lead to an alterna-
tion between two different material assignments. This might turn into non-negligible
changes (of 4%) in dose distributions, particularly in the boundaries of materials with
substantially different atomic number. This issue might be solved in the forthcoming
version of AXB. Some authors have given details on AXB version 11.0.02, a pre-clinical
engineering release160;161. One of the main differences between the two AXB versions
(10 and 11) is given by the different strategy in the density-to-media assignment, as
shown in table 5.6. With respect to version 10, version 11 includes a refinement related
to the issue discussed herein. Apart from including automatic assignment of the Air
material to very low density regions inside body, the density range per each material
was slightly extended with an overlap of densities between adjacent materials. In the
overlapping range, the elemental composition is considered as a proportional mixture
of the previous and next material. Note the large overlap between cartilage and bone;
for these two tissues, the difference in calcium content plays a fundamental role in the
dose calculation phase (to medium and/or water)160.
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Material
Density (g/cm3)
Low High
Air 0.000 0.020
Lung 0.011 0.624
Adipose tissue 0.554 1.001
Muscle, skeletal 0.970 1.093
Cartilage 1.056 1.600
Bone 1.100 3.000
Table 5.6: Material mass densities in AXB (v.11.0.02). From Fogliata et al. 160 .
5.4 Conclusions
We evaluated the dose accuracy provided by the AXB (v.10.0.28) advanced dose cal-
culation algorithm inside tissue heterogeneities by means of both experimental mea-
surements (IC, TLD and EBT films) and MC simulations for the first time. For 6
MV and 18 MV and different field sizes, PDD curves and dose profiles were evaluated
on two slab water phantoms: one containing lung-equivalent material and another one
containing bone-equivalent material. We also included AAA in the comparisons as the
current standard in EclipseTM.
The experimental measurements were in good agreement (within statistical uncer-
tainties) with MC in all cases. Remaining differences may originate from the fact that
MC simulations used biological materials whereas plastics were used in the experimental
setup.
Generally, the accuracy provided by AXB was comparable to that of MC simu-
lations in all situations. Central-axis depth-dose curves predicted by AXB were in
good agreement with MC and experimental measurements for the phantom with the
lung-equivalent heterogeneity. On the contrary, AAA v.10.0.28 was unable to correctly
predict the dose in lung when the beam energy was set to 18 MV and the field size to
2 × 2 cm2. Moreover, AAA tended to overestimate the dose in the water region after
the lung-equivalent material. In bone, an excellent agreement was found between AXB
and MC in terms of Dm. Discrepancies were more significant when comparing in terms
of Dw. The question of which quantity—Dw or Dm—should be adopted for comparison
purposes is still under debate83;86 and there are strong arguments both for using one
or the other. However, from the results found in this study we suggest that the dose is
compared in terms of Dm preferably for the benchmarking of the algorithm with MC.
In contrast to AXB, doses reported by AAA were highly inaccurate in bone, where the
results were closer to those of AXB and MC in terms of Dm—despite AAA reports Dw.
AXB was able to correctly predict the widening and shrinking effects in beam
penumbrae of dose profiles relative to those in water due to the presence of low-density
or high-density materials, respectively. These results are in good agreement with recent
publications147;153. AAA did not properly predict the widening effect of the beam
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penumbra in lung, but lateral profiles in bone were obtained with reasonable accuracy
since the penumbra shrinking phenomenon in bone is mild. The results are consistent
with previous studies58;147.
CT acquisition yielded slight fluctuations of HU-values in the regions adjacent to
the heterogeneities which affected the materials assignment in the different regions
of the phantoms. AXB and MC dose distributions were influenced by the material
assignment in both phantom configurations. Consequently, dose differences up to 4%
were found in the water region before the lung heterogeneity when comparing against
the PDD curves calculated on virtual phantoms—where a single HU-value was manually
assigned to each region of the phantoms. On the contrary, AAA dose distributions were
unaltered by the density change of the voxels when using CT images. One should bear
this in mind when comparing AXB version 10 dose distributions against experimental
measurements. This issue might be solved in the forthcoming clinical version 11.
In conclusion, AXB provides comparable results to MC simulations under similar
conditions. Hence, AXB is a good alternative to MC and undoubtedly represents a
significant improvement over the widely-used AAA.
Chapter 6
Quantifying lateral tissue
heterogeneities in proton therapy
fields
This section was partially developed at the Massachusetts General Hospital (MGH) &
Harvard Medical School in Boston, Massachusetts, USA.
6.1 The need for Monte Carlo dose calculation in proton
therapy
Proton therapy has become one of the most attractive modalities for the treatment
of cancer due to the unique dosimetric features of protons162–164. The characteristic
depth-dose distributions of proton beams (see figure 1.2 in chapter 1) result in a signifi-
cantly reduced integral dose compared to photon treatments. These physical attributes,
in turn, increase the impact of uncertainties in the delivered dose. As mentioned in
chapter 1 section 1.3, these uncertainties arise from the planned dose distributions pre-
dicted by dose calculation algorithms15, imaging or delivery uncertainties and inter-
or intra-fractional geometry changes16;17. In this study we focus on the uncertain-
ties in dose distributions predicted by the treatment planning system arising from the
complexity of the patient geometry.
Modern pencil beam algorithms account for proton energy losses and Coulomb scat-
tering, but the physical models exhibit dosimetric limitations that become noticeable
for highly inhomogeneous media. Thus, analytical calculation models can predict dose
distributions with an acceptable precision in simple geometries78;165, but uncertain-
ties still remain in the presence of complex density heterogeneities within the beam
path. Although attempts have been made to account for heterogeneities lateral to
the beam direction78;166;167, pencil beam algorithms commonly use a one-dimensional
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dose-scaling method of a proton pencil beam in water. Thus, the multiple Coulomb
scattering in modeled in the dose kernel but the radial distribution at each depth only
accounts for inhomogeneities upstream of the pencil’s central axis81. The assumption
of such slab geometry might induce dose errors in the presence of lateral heterogeneities
that result in significant difference between the planned and delivered dose to the target
volume.
Special considerations must be taken into account when the target volume is re-
duced. Firstly, small lesions often require high-dose single-fraction treatments involving
a small number of fields, i.e. potential errors from one field will not be compensated by
other fields. Secondly, the smaller the field size, the lower the number of pencil kernels
involved in the calculation and therefore, the higher the effect of dose inaccuracies of
single pencil kernels on the final convolution. Further, the dosimetry of small pro-
ton beams is challenging from a planning and delivery perspective because of aperture
scattering and charged particle disequilibrium—fields with aperture diameters smaller
than ≈ 7 cm require field-specific output factor corrections to compensate for aperture
scattering effects168. The impact of small proton fields on dose calculations has been
previously studied169;170. Bednarz, Daartz, and Paganetti 171 evaluated the accuracy of
dose distributions predicted by a pencil beam algorithm in the XiO treatment planning
system for a set of patients with small lesions. The authors pointed out the dosimetric
limitations of the algorithm resulting in hot and cold spots and range degradation in
the target volume due to scattering in heterogeneities. Although the reported discrep-
ancies appeared clinically acceptable (< 3%19) over the multiple fields conforming the
treatment, differences up to 8.6% in the dose covering at least 95% of the target volume
(D95) were found for a single field.
As mentioned in chapter 1 section 1.4.2, Monte Carlo (MC) computations are con-
sidered the golden standard for dose calculation in radiotherapy and are expected to
be especially valuable in those situations where the limitations of dose calculation al-
gorithms appear to be more prominent, e.g. for small fields in the presence of hetero-
geneities172. However, MC dose calculations might be time-consuming. On the other
hand, for the cases where the expected errors in the planned dose exceed a particular
tolerance level, devoting some time to obtain a more reliable dose distribution might
be undoubtedly worthwhile.
The aim of this study was to obtain a fast and easy-to-calculate indicator that
predicts the reliability of planned dose distributions for small passively scattered proton
beams based on the level of tissue inhomogeneities in the patient and evaluates the
potential need for Monte Carlo dose calculations. For this purpose, the accuracy of the
treatment planning process was assessed by comparing the planned dose distributions
to Monte Carlo simulations for a set of small proton therapy fields. The differences
in the dose covering at least 50% of the gross tumor volume (D50) between the pencil
beam algorithm predictions and the Monte Carlo calculations were evaluated for the
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selected fields. A heterogeneity index (HI) was introduced by Pflugfelder et al. 79 as
a method to quantify lateral tissue heterogeneities of scanned proton beams. Based
on this concept, a HI for passively scattered proton beams was proposed in this study.
The HI was intended to (i) entail a simple calculation methodology and (ii) require a
short computation time. Finally, the correlation between the differences in D50 and the
tissue heterogeneities within the beam path as parameterized by the HI was analyzed.
6.2 Methodology
6.2.1 Patient population
Fourteen head and neck patients (A-N) treated at our facility with proton beams were
selected. The study was done under IRB approval (IRB protocol 2010-P-002050/1;
MGH: ”Improving treatment planning and dose prediction in radiation therapy by
retrospective data analysis.”).
The gross tumour volumes (GTVs) ranged from 0.1 cc to 30 cc.
Eight patients (A-H) were stereotactic patients and six (I-N) required fractionated
radiotherapy. A total of 38 fields were analyzed.
The relevant characteristics of the selected clinical cases are summarized in table
6.1.
To define a field size parameter, we computed the diameter of the aperture as that
of a circle with the same area as the actual field. Field sizes defined accordingly ranged
from 2 cm to 7 cm diameter (φ). Field sizes smaller than φ = 2 cm were excluded
from this study because they are prone to uncertainties in the output factor correction
required to compensate for aperture scattering effects168. These effects might alter
the prediction of the error made by the analytical algorithm based on the geometrical
complexity of the patient exclusively. The analysis of these effects is beyond the scope
of this chapter.
6.2.2 Patient dose evaluations
6.2.2.1 Treatment planning system at MGH
The treatment planning system CMS/XiO (XiO, Computerized Medical Systems Inc.)
uses an in-house PB algorithm which is based on the physics model developed by Hong
et al. 81 in terms of modeling device effects and lateral spread. At each point, the dose
D(x, y, z) of a single pencil kernel is factorized into a depth-scaled central axis dose
C(z) and a lateral fluence distribution O(x, y, z):
D(x, y, z) = C(z) ·O(x, y, z) (6.1)
The off-axis term is approximated by a Gaussian profile:
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φfield(cm)
Patient GTV (cc) φ1 φ2 φ3 φ4 φ5 φ6 φ7 φ8 φ9 φ10
A 0.90 2.7 2.1 2.1 - - - - - - -
B 0.18 2.2 2.3 - - - - - - - -
C 0.07 2.7 - - - - - - - - -
D 0.75 1.9 1.9 2.3 - - - - - - -
E 7.49 5.0 4.9 3.5 3.5 - - - - - -
F 30.1 6.7 6.7 5.9 - - - - - - -
G 11.4 6.5 6.1 - - - - - - - -
H 1.13 2.2 2.2 2.2 - - - - - - -
I 3.00 3.9 3.7 3.7 3.5 3.7 3.7 2.5 2.5 2.4 2.5
J 2.64 2.9 - - - - - - - - -
K 21.5 4.5 - - - - - - - - -
L 3.75 4.8 2.5 - - - - - - - -
M 12.0 5.0 - - - - - - - - -
N 27.9 6.8 7.1 - - - - - - - -
Table 6.1: Tumour volume (GTV) and field size (aperture diameter, φ) for the selected patients.
O(x, y, z) =
1
2pi[σ(z)]2
exp
(
− x
2 + y2
2pi[σ(z)]2
)
(6.2)
where σ(z) is the standard deviation and it is determined by adding the contribu-
tions of the virtual source size (σsrc(z)), the scatter in the range compensator (σrc(z))
and the scatter in the patient (σp(z)) (please see Hong et al.
81 for more details):
σ(z)2 = σsrc(z)
2 + σrc(z)
2 + σp(z)
2 (6.3)
Currently, all treatment plans at MGH are based on this PB. Plans were generated by
Brian Winey.
As in other analytical algorithms, the dose calculation is based on the water-
equivalent properties of each CT voxel. Thus, a look-up table is used to convert HU
into relative stopping power. The dose distribution calculated by XiO is a relative dose
distribution to the prescribed dose to the target volume.
The beam output factor is defined at our facility as the dose delivered at the calibra-
tion point divided by the required monitor units (MU) given by an ionization chamber
located in the treatment head. Since XiO does not model the treatment head to per-
form the dose computation, output factors—or absolute doses—need to be modeled or
measured at our facility. Models to predict such output factors were established for a
large set of ranges considering standard machine settings with standard aperture sizes
and no range compensator173. Daartz et al. 168 quantified the effect of the field size on
the output factor to validate dose calculations by performing measurements for a set of
aperture sizes and ranges. The results revealed a remarkable influence of the aperture
size on the output factor. Therefore, a field-size specific correction factor is applied
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clinically to correct the measured/modeled output168.
6.2.2.2 MC simulations for proton dose calculations
All simulations were performed with TOPAS30;31 (see chapter 3 section 3.1.3.1 for more
details).
The dose computation is based on the CT of the patient. The conversion from HU
to elemental composition and mass density of each voxel is done according to Schneider,
Bortfeld, and Schlegel 88 with an extension to deal with high HU corresponding to high-
density materials (e.g. titanium)174. To account for the CT scanner properties at the
MGH, a density correction factor is applied to normalize the density used by MC to
match the HU versus relative stopping power table integrated in the planning system.
The simulation was done in two steps, as stated earlier in this manuscript (see
section 3.1.3.4). First, protons were tracked through the treatment head (nozzle).
The particle type, energy, position and angular momentum for particles that crossed
a plane at the exit of the treatment head (after the field-specific devices—aperture
and compensator) were stored in a phase space file. For the field sizes considered,
the simulation efficiency through the nozzle was only about 3% for the smallest fields,
i.e. only 3% of the protons at nozzle entrance reached the patient. A total of 108
histories were simulated per field to ensure the statistical uncertainty to be < 1%
for doses in the target volume. In order to reduce computation times and improve
the statistics of the results, the calculations were split into 20 separate—statistically
independent—simulations that ran in parallel on 20 separate CPUs. Each of the 20
separate simulations took ≈ 12 hours to complete on a single node of the computing
cluster with a 3 GHz CPU. The second step tracked the particles stored in the phase
space plane through the patient geometry. The calculation time for in this step ranged
from 1.5 to 5 hours for a single calculation on the same computing nodes. Variance
reduction techniques were implemented in the code to reduce computation time and
statistical uncertainties108. Two particle split planes were defined inside the treatment
head and protons reaching these planes were split into 4 protons with their weight
adjusted accordingly.
In order to obtain absolute doses, the dose at the center of the SOBP in a water
phantom was calculated in a separate simulation. This calibration was performed
for an open field without aperture and compensator. The MC was re-normalized by
the appropriate field-size correction factor mentioned in section 6.2.2.1. Instead of
being taken from Daartz et al. 168 , output factors were calculated with TOPAS for
each selected beam by computing the quotient of the dose at the center of the SOBP
simulated with and without the specific aperture. The computed output factors were
generally in good agreement with those derived from the table in Daartz et al. 168
(differences below 2%).
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6.2.2.3 Dose comparisons
The dose grid reported by XiO is coarser than the CT grid. MC simulations were
performed on the CT grid with the XiO scoring grid layered on top of the CT grid
in a parallel world. Parallel worlds is a Geant4 feature that allows objects—such as
scoring grids—to be placed on top of physical volumes without affecting the physics
processes and simulations. Whenever a particle deposits energy, this energy is converted
to the equivalent dose using the material of the CT voxel in which the energy deposit
happened. The dose is then scored in the parallel XiO grid. The final dose distribution
on the XiO grid is the sum of all energy deposits from all histories in the simulations.
The MC dose was reported on the planning grid for comparison purposes.
The MC computations were tailored to yield dose to water using the methodology
described by Paganetti 85 .
The discrepancies in the dose that the 50% of the GTV receives, D50, were assessed.
Although the mean dose to the target is commonly used, we believe it is not the most
appropriate in this case because it can be insensitive to hot and cold spots within
the region of interest—the presence of underexposed and over-irradiated regions can
compensate each other.
6.2.3 A Heterogeneity Index HI
We aimed at finding a parametrization to quantify the complexity of tissue hetero-
geneities within the beam path. Pflugfelder et al. 79 presented the concept of the HI as
a method to assess the lateral tissue heterogeneities for scanned proton beams. From
this fundamental idea, we developed a novel technique to obtain a HI for passively
scattered proton beams according to the dose calculation approach taken by the PB
algorithm used at MGH.
6.2.3.1 Definition
The HI computation was based on the CT of the patient. To evaluate the tissue
heterogeneities we assessed the relative stopping power (Srel) of each CT voxel. The
conversion from HU to Srel was obtained from the calibration curve of our CT scanner.
For the definition of HI the coordinate system was set so that the central axis of
the proton beam coincides with the z axis, its origin is at the surface of the patient and
the z axis points towards the isocenter.
An HI-value was defined for each treatment field individually. For passively-scattered
proton beams the 3D dose calculation results from the convolution of several pencil ker-
nels. Hence, the HI was defined as of the contribution of a number n of indexes HIi,
one defined for each pencil kernel i.
The index associated to a pencil kernel i, HIi, whose central axis is located at
P = (xi, yi), is defined as follows. First, at a depth zk, HIik is computed as the sum
CHAPTER 6. QUANTIFYING LATERAL TISSUE HETEROGENEITIES IN
PROTON THERAPY FIELDS 107
of the square differences between Srel of the surrounding points on the x − y plane
and Srel of the central axis of the kernel, weighted by the lateral fluence distribution
(φ(xj , yj , zk)):
HIik(xi, yi) =
∑
j∈Ti(zk) φi(xj , yj , zk) · [Srel(xj , yj , zk)− Srel(xi, yi, zk)]
2∑
j∈Ti(zk) φi(xj , yj , zk)
(6.4)
where Ti(zk) is the appropriate set of sampling points in the x − y plane at depth
zk. The lateral fluence φ(xj , yj , zk) is approximated by a Gaussian distribution with
standard deviation σi(zk), as described in section 6.2.2.1 (equation 6.3). σi(zk) deter-
mines Ti(zk); all points closer than 3σi(zk) to the central axis of the pencil kernel i are
considered for the calculation.
Then, lateral tissue heterogeneities computed at each depth as described in equation
6.4 are assessed from the surface of the patient, z0 = 0, up to a depth equal to the
prescribed range after the compensator, Ri (in water equivalent distance). The index
associated to the pencil kernel i is the addition along the studied length:
HIi(xi, yi) =
k=Ri∑
k=0
HIik (6.5)
The surface of the patient was considered to be the skin contour delineated during
the planning process for each patient. No contributions were considered outside this
contour. Ri was was defined as the prescribed range in water (R
′)—distal 90% dose
level of the SOBP—minus the maximum thickness of the range compensator expressed
in terms of water-equivalent thickness (rcw): Ri = R
′ − rcw. Thus, a single Ri, named
R, was used regardless of the location of the pencil kernel. In our case, this was a
good approximation since for small target volumes the modulation of the range com-
pensator over the target volume area is small—usually below 5 mm. Therefore, the
error associated with this assumption is considered to be small.
The computations described in equations 6.4 and 6.5 are performed for each pencil
kernel involved in the dose calculation. Finally, the HI associated with the proton beam
is defined as the median of the indexes HIi(xi, yi) for all pencil kernels:
HI =
[
H˜Ii
]1/2
i∈A
(6.6)
where A represents the beam effective area within which pencil kernels are sampled.
Voxels receiving a dose higher than 90% of the maximum dose at the isocenter slice
were considered to belong to A. We sampled the pencil kernels within A on the CT so
that the spacing between them was 2 mm—the spacing used by the analytical algorithm
(set by manufacturers for the optimization). The sampling points were taken from the
existing voxels of the CT grid. The size of the selected area determined the number of
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pencil kernels.
The median provides a measure that is more robust than the mean in the presence of
outliers or extreme values, which can increase the mean of the indexes HIi considerably
without altering the dose to the 50% of the GTV volume substantially.
The aforementioned description of the calculation of the HI is represented schemat-
ically in steps in figure 6.1.
With this parametrization, heterogeneities lateral to the central axis of each pencil
kernel will increase HI. For a homogeneous phantom HI would be zero. Note that HI
as defined in this section is unitless.
(a) At a particular depth zk of the pencil
central axis.
(b) Selection of the central axis voxel at
zk.
(c) Selection of all surrounding voxels ¡
3σ(zk).
(d) Computation of square differences of
Srel-values.
(e) Repetition at all depths. (f) Integration for all pencil kernels in the
field.
Figure 6.1: Schematic representation in steps of the HI calculation.
6.2.3.2 Setup and practical considerations for the HI calculation
All information involved in the HI calculation was available from the treatment planning
system.
For a particular patient, plan and treatment field, a user interface was used to
generate a text file that contained relevant information. Among others, the following
data relevant for this study was gathered in this file: number and dimension of CT
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voxels in x, y and z (nx, ny, nz and dx, dy, dz, respectively), dimensions of the CT
cube, gantry angle (αg), couch angle (βc), isocenter position, prescribed range in water
(R′), maximum thickness of the range compensator (rc) and prescribed dose.
The 3D dose distribution from the treatment planning was used to select the CT
voxels traversed by the proton beam. The planning system reports the dose on a grid
that is coarser than the CT grid. Moreover, it has its own coordinates system whose
origin is shifted with respect to the CT origin. The size of the planning grid is stored
in the text header of the dose distribution file and the offset between the 3D planned
dose and the CT is specified in the aforementioned text file. With this information, the
CT and the 3D planned dose were co-registered. In this step the dose distribution was
re-sampled on the CT grid to maintain the highest possible resolution regarding Srel
assignments.
To simplify the calculation of the HI described in section 6.2.3.1, the CT grid was
rotated according to αg and βc for each field so that the CT voxels align parallel
to the beam axis. Both the CT and planned dose distribution were re-sampled in this
new rotated grid by interpolating Srel and dose values—thereby, each z slice of the dose
distribution was a 2D representation of the beam lateral dose profile. This interpolation
of Srel represents a source of uncertainty regarding material assignments that might be
significant when analyzing voxels individually. However, the error added in this step
does not affect HI substantially since the index encompasses the global contribution of
several hundreds of voxels within the beam path; therefore, voxel-specific differences in
Srel-values have a negligible effect in the HI.
Eventually, the HI is intended to be implemented in the clinical routine. Conse-
quently, the HI was designed to entail a fast calculation and be easy to implement if
readers intent to use our formalism in their planning environment.
6.3 Results
6.3.1 Comparison between MC and analytical dose calculations
For the set of patients selected the DVHs predicted by the PB algorithm were compared
against those derived from MC dose calculation on a field-by-field basis. A maximum
difference of 5.4% in D50 was found for one of the fields of patient G (figure 6.2).
Figures 6.2-6.4 show the DVH comparison for one of the fields of patients G, D and
I, respectively. Among these three examples the largest difference was found for the
field of patient G, with a discrepancy in D50 of 5.4%. The beam delivery based on XiO
overestimated the dose to the GTV by 3.4% for the field displayed for patient D. The
difference observed for patient I was within MC uncertainties (0.8%).
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Figure 6.2: DVHs and comparison of the dose distribution predicted by the treatment planning
system (PBA) and the MC dose calculation (MC) for one of the fields of patient G. The GTV and
several organs-at-risk were considered.
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Figure 6.3: DVHs and comparison of the dose distribution predicted by the treatment planning
system (PB) and the MC dose calculation (MC) for one of the fields of patient D. The GTV and
several organs-at-risk were considered.
6.3.2 HI-values
The heterogeneities within the proton beam path were analyzed as described in section
6.2.3 for the set of patients selected. The whole process to obtain the HI-values for
each field—including the co-registration procedure, the assessment of σi(z) and the HI
calculation—took less than 3 minutes to complete on both, a single Windows computer
with an Intel R©CoreTMi5 processor (2.4 GHz) or a single iMac with an Intel R©CoreTM2
Duo processor (2 GHz). The HI values obtained for each studied field ranged from 0.9
for the field with the most homogeneous beam path (patient I, φ4), to 3.4 for the field
traversing the greatest level of heterogeneities (patient G, φ = 2).
In figures 6.5-6.7 three of the studied proton beams are depicted. The fields are
CHAPTER 6. QUANTIFYING LATERAL TISSUE HETEROGENEITIES IN
PROTON THERAPY FIELDS 111
(a)
0 0.5 1 1.5 2 2.5 3 3.5
0
20
40
60
80
100
120
D(Gy)
vo
lu
m
e(%
)
 
 
PB
MC TOPAS
GTV
pituitary
brainstem
cochlea
(b)
Figure 6.4: DVHs and comparison of the dose distribution predicted by the treatment planning
system (PB) and the MC dose calculation (MC) for one of the fields of patient I. The GTV and several
organs-at-risk were considered.
from patients G, D and I, respectively, and correspond to the same fields for which
the DVH comparison is shown in the previous section. In each figure, the images
correspond to the isocentric slices of the CT and the planned dose distribution after
the co-registration—images (a) and (b), respectively—, and the CT voxels traversed
by the proton beam—image (c). The field of patient G had an associated HI-value of
3.39 and the index associated to the field of patient I was 1.01. The field belonging to
patient D had an intermediate HI-value of 1.73.
The HI-values obtained were well correlated to the level of tissue inhomogeneity
as seen in the third-column images of figures 6.5-6.7. The field shown for patient G
traversed a complex heterogeneous region with bony structures. In the case of patient D,
a small region of high-density tissue was within the beam path. Finally, the complexity
of the tissue traversed by the field of patient I was substantially lower than the first
two examples, and so was its HI-value.
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(c) Beam path
Figure 6.5: Patient G, αg = 125
o, βc = 0
o . HI-value is 3.39. Difference in D50 is 5.4%.
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(c) Sampling voxels
Figure 6.6: Patient D, αg = 325
o, βc = 0
o. HI value is 1.73. Difference in D50 is 3.4%.
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Figure 6.7: Patient I, αg = 270
o, βc = 0
o. HI value is 1.01. Difference in D50 is 0.8%.
6.3.3 HI vs. dose discrepancies
Figure 6.8 shows the differences in dose to the GTV (in terms of D50) between our PB
algorithm predictions and the MC calculations as a function of HI. Each point repre-
sents a single field. Statistical uncertainties associated with the MC dose calculations
were within 1-2%; error bars are not shown in the graph for clarity.
A strong correlation (Spearman’s rank correlation coefficient175: ρ=0.8, p< 0.0001)
was found between our implementation of HI and the discrepancies in dose for the
studied fields. Among the analyzed fields only two might be labeled as outliers (located
in the lower-right quadrant of figure 6.8. In these two cases, despite the beam path
being quite inhomogeneous according to their associated HI-values (1.87 and 2.60) the
analytical algorithm agrees well with the MC calculations for the dose to 50% of the
GTV (discrepancies with respect to MC are below 0.1% and around 1.4%, respectively).
In these cases, under and over-dosage due to multiple Coulomb scattering may have
canceled out.
A line was fitted to the data to help the reader see the correlation. A threshold
value for HI, HIT , can be determined from this fit for a given tolerance level.
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Figure 6.8: Absolute differences (in %) in the dose covering 50% of the GTV volume (D50) (i)
derived from our treatment planning system based on analytical dose calculations and (ii) calculated
with MC as a function of HI for the studied patients. Each point represents a single field.
6.4 Discussion
We have confirmed that PB algorithms can not properly predict the dose to the tar-
get in the presence of complex lateral tissue heterogeneities for small proton beams,
as reported previously171. The reason lies in the approximation of multiple Coulomb
scattering, which breaks down in complex geometries15. Some of the differences for sin-
gle fields found exceeded the tolerance levels commonly accepted in treatment delivery.
However, over multiple fields, all treatments were within clinical tolerance levels.
The heterogeneity index, HI, presented in this study parameterizes the inhomogene-
ity of the tissue traversed by passively scattered proton beams. The HI was formulated
according to the calculation approach taken by a PB algorithm that is based on the
physics model developed by Hong et al. 81 and can thus be applied in general to al-
gorithms based on it. HI-values for each field were obtained in less than 3 minutes
fulfilling our primary goal to provide a fast calculation to estimate the necessity for
MC simulations.
The HI-approach presented here works best for small proton fields, such as those
included in this study. For larger fields, variations in HI within the field might be too
large to allow a characterization of the geometry based on an average HI alone. Very
small fields were excluded from this study (aperture diameters < 2cm) for the following
reasons. For such small fields, the aperture is so small that electronic equilibrium is
substantially compromised and experimental investigations might be required in addi-
tion to perform dose calculations by the planning system with a field-size dependent
output factor correction. Effects from aperture scattering, air gap sizes, compensator
scattering and scattering inside the patient (not related to the heterogeneity) contribute
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more to dose differences than the scattering caused by the heterogeneity of the patient.
Differences in the delivered dose to the target—in terms of D50—between the pre-
dictions by the treatment planning system and the MC calculations were found to be
strongly correlated to HI, as shown in figure 6.8. With the established relation, a toler-
ance level of 2.5% leads to a threshold HI-value of 1.73. Indices below this value indicate
that dose delivery errors are very likely to be within the clinical tolerance (< 3%). For
those HI-values exceeding the threshold, analytical dose calculations become prone to
clinically significant errors. Only two cases—5% of the total fields studied—seemed
not to fit this tendency and showed lower discrepancies in D50 than expected based on
their associated HI-value.
HI-values close to the established threshold will not be conclusive. Based on the
overall impact on the complete treatment, other aspects—such as the total number of
fields involved in the treatment—should be taken into account in addition to the HI to
finally decide whether or not MC calculations are needed for a particular case.
The definition of HI presented in this study is adjusted to the GTV volume. If the
volume of interest was different, such as the PTV, the methodology should be subtly
adapted so that the pencils sampling area would cover the whole volume.
6.5 Conclusions
Depending on their distribution relative to the treatment field and on the field size,
density heterogeneities are difficult to handle correctly by pencil beam algorithms,
mainly due to range degradation effects caused by multiple Coulomb scattering. For
small fields, analytical calculations in patients might misevaluate the dose in the target
volume by several percent when the proton beam is traversing a highly inhomogeneous
region.
In this study we suggested a simple and fast methodology, the heterogeneity index,
HI, to estimate the tissue inhomogeneities traversed by a small proton beam. The
complexity of tissue heterogeneities quantified in this way was found to be strongly
correlated to the dose differences within the target volume between the treatment plan-
ning system and the Monte Carlo calculations. The higher the level of inhomogeneities
within the beam path, the larger the discrepancies found. Consequently, the HI can be
used to predict whether a specific field arrangement is associated to considerable abso-
lute dose uncertainties. In that case, this methodology suggests that either a change in
the beam incidence (if feasible) or a Monte Carlo dose calculation of the plan should be
considered. Other aspects will influence the final decision based on the particularities
of each case.
The HI involves a very short computation time—the whole procedure to obtain the
index takes less than 3 minutes to complete on a single Windows or iMac with 2 GHz
processor. Therefore, the HI can be implemented in the clinical routine as a potential
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indicator of the need for treatment plan verification with Monte Carlo simulations.
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Conclusions
This thesis was devoted to solve some of the current concerns on the absorbed dose
determination in the presence of tissue heterogeneities in external radiotherapy.
According to the outline presented in section 2, the main achievements and contri-
butions of this thesis are listed below:
I. Two different Monte Carlo (MC) codes have been successfully employed to provide
reliable calculations that were used as the reference throughout the development of the
tasks involved in this thesis, both for photon and for proton therapy fields.
II. This thesis has provided knowledge of the suitability of several detectors to ac-
curately determine the absorbed dose in bone for megavoltage (MV) photon beams.
LiF:Mg,Cu,P (MCP-Ns and TLD-2000F) and LiF:Mg,Ti (MTS-7s) ultra-thin thermo-
luminescent dosimeters (TLDs), as well as radiochromic films (EBT), were considered
assuming that their reduced size might entail low perturbation effects at first approxi-
mation.
• MCP-Ns, MTS-7s and TLD-2000F were found to be suitable for absorbed dose
measurements in radiotherapy showing no significant energy dependence (varia-
tions within 2.5%) neither for megavoltage photon (including flattening-filter-free
energies) nor electron beams. MCP-Ns and TLD-2000F exhibited a linear re-
sponse with the absorbed dose whereas the use of MTS-7s deserves a word of
caution due to their two-step supra-linear response—MTS-7s must be calibrated
within the appropriate linearity range.
• The use of MCP-Ns, MTS-7s and EBT for the absorbed dose determination in
the presence of bone requires the application of a perturbation correction factor
of the order of 4-5%.
• Among the detectors studied herein, TLD-2000F (20µm-thick cylindrical films)
would be the detector of choice for accurate absorbed dose measurements in bone
providing negligible (<2%)—though observable—electron energy fluence pertur-
bation effects. However, the MC simulations revealed that a detector up to 50µm-
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thick would be small enough to provide reliable dose measurements regardless of
its material composition.
III. This thesis has contributed to the thorough examination of the behavior of Acuros
XB v.10.0.28 (AXB) in the presence of high-density and low-density heterogeneities.
• The accuracy provided by AXB was comparable to that of MC simulations (agree-
ment within 2%) under similar conditions both in the presence of lung and bone
and therefore, AXB represents an undoubtedly improvement over the worldwide-
used current standard algorithms based on analytical calculations.
• The discrete nature of the material assignment in AXB in combination with small
Hounsfield Units (HU) (i.e. density) fluctuations caused by artifacts originated
during CT image acquisition especially around the interfaces leaded to significant
changes (4%) on the absolute dose calculation. This rapid alternation between
two different material assignments must be born in mind when comparing against
experimental measurements, which will not be affected by such CT image arti-
facts. Forthcoming versions of AXB might have solved this issue.
IV. This thesis has released an algorithm—the heterogeneity index (HI)—to easily
predict the expected dose uncertainties during treatment planning based on the quan-
tification of patient tissue heterogeneities within the beam path. The HI can be used
to assess the potential need for MC dose calculations.
• The HI was a good estimator of the complexity of the tissue inhomogeneities
traversed by the particle beam. Its calculation entailed a very short computation
time allowing its application in the clinical routine without interfering with the
workflow.
• Analytical dose calculation algorithms cannot properly predict the dose to the
target volume in the presence of complex density heterogeneities when small pro-
ton beams are being delivered and differences to MC dose calculations might
exceed the clinical tolerance levels commonly accepted in treatment planning.
• The HI was found to be a good indicator for the accuracy of dose distributions
predicted analytical dose calculation algorithms and therefore, it can be used to
easily predict whether a MC dose calculation should be considered for a particular
patient.
Along this line, the main results of the thesis have been published in scientific jour-
nals and presented at professional society meetings.
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All in all, it can be concluded that some of the issues on the absorbed dose deter-
mination in the presence of tissue heterogeneities addressed in this thesis still deserve
further research. As for photons therapy, forthcoming versions of AXB should be stud-
ied to test the impact of the material assignment procedure on the dose distributions
in more complex geometries to estimate the influence in the patient outcome for a
complete treatment. Further, the calculation of perturbation correction factors for ion-
ization chambers in high-density and low-density heterogeneities would be of utmost
interest. As for proton therapy, the availability of an algorithm capable of dealing with
heterogeneities with high accuracy would be a further step towards dose calculation
during treatment planning.
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